US20030070584A1 - Dip coating compositions containing cellulose ethers - Google Patents

Dip coating compositions containing cellulose ethers Download PDF

Info

Publication number
US20030070584A1
US20030070584A1 US10122999 US12299902A US2003070584A1 US 20030070584 A1 US20030070584 A1 US 20030070584A1 US 10122999 US10122999 US 10122999 US 12299902 A US12299902 A US 12299902A US 2003070584 A1 US2003070584 A1 US 2003070584A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
percent
composition
coating
subcoating
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10122999
Inventor
Cynthia Gulian
Walter Gowan
Kishor Parekh
Joseph Morris
Thomas Markley
Dennis Wieand
Gerard McNally
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
Johnson and Johnson Consumer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • A61K9/2826Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Abstract

Water soluble, gelatin-free dip coatings for pharmaceutical solid dosage forms such as tablets comprising HPMC and xanthan gum, carrageenan, and mixtures thereof, or HPMC and castor oil or maltodextrin.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This Application claims the benefit of U.S. Application No. 60/291,127 filed on May 15, 2001 and U.S. Application No. 60/325,726 filed Sep. 28, 2001, which are both incorporated by reference in their entireties herein.[0001]
  • FIELD OF THE INVENTION
  • This invention relates to novel, water soluble, gelatin-free compositions for dip coating substrates, such as tablets and capsules, and methods for producing such dosage forms. This invention further relates to a method for increasing the weight gain of a water soluble, gelatin-free, film forming coating on a dip-coated tablet or caplet. [0002]
  • BACKGROUND OF THE INVENTION
  • During most of this century, hard gelatin capsules were a popular dosage form for prescription and over-the-counter (OTC) drugs. The ability to combine capsule halves having different colors provided manufacturers with a unique means of distinguishing various pharmaceutical products. Many patients preferred capsules over tablets, perceiving them as being easier to swallow. This consumer preference prompted pharmaceutical manufacturers to market certain products in capsule form even when they were also available in tablet form. [0003]
  • Generally, empty hard gelatin capsules are manufactured using automated equipment. This equipment employs rows of stainless steel pins, mounted on bars or plates, which are dipped into a gelatin solution maintained at a uniform temperature and fluidity. The pins are then withdrawn from the gelatin solution, rotated, and then inserted into drying kilns through which a strong blast of filtered air with controlled humidity is forced. A crude capsule half is thus formed over each pin during drying. Each capsule half is then stripped, trimmed to uniform length, filled and joined to an appropriate mating half. [0004]
  • An alternative to capsule products are caplets, which are solid, oblong tablets that are often coated with various polymers such as cellulose ethers to improve their aesthetics, stability, and swallowability. Typically, such polymers are applied to the tablets either from solution in organic solvents, or from aqueous dispersion via spraying. However, such spray-coated tablets lack the shiny surface and elegance of the hard gelatin capsules. Additionally, it is not commercially feasible to spray-coat a tablet with a different color coating on each end. [0005]
  • Another alternative to capsule products are “gelcaps,” which are elegant, shiny, consumer-preferred dosage forms that are prepared by dipping each half of an elongated tablet in two different colors of gelatin solution. See U.S. Pat. Nos.: 4,820,524; 5,538,125; 5,685,589; 5,770,225; 5,198,227; and 5,296,233, which are all incorporated by reference herein. A similar dosage form, commercially available as a “geltab,” is prepared by dipping each half of a round, convex tablet into different colors of gelatin solution, as described in U.S. Pat. Nos. 5,228,916, US5,436,026 and US5,679,406, which are all incorporated by reference herein. As used herein, such “gelcaps” and “geltabs” shall be included within the broader term, “tablets.”[0006]
  • However, the use of gelatin as a pharmaceutical coating material presents certain disadvantages and limitations, including the potential for decreased dissolution rate after extended storage due to cross-linking of the gelatin, potential for microbial contamination of the gelatin solution during processing, and long processing times due to extensive drying requirements. Further, the energy-related costs associated with gelatin coatings tend to be high since the gelatin material is typically applied to the substrates at an elevated temperature of at least about 40° C. in order to maintain fluidity of the gelatin, while the substrates are maintained at about 50° C. in order to minimize microbial growth. [0007]
  • Various attempts have been made to produce gelatin-free hard shell capsules. For example, WO 00/18835 discloses the combination of starch ethers or oxidized starch and hydrocolloids for use in preparing hard capsule shells via conventional dip molding processing. See also U.S. Pat. No. 4,001211 (capsules prepared via pin dip coating with thermogelled methylcellulose ether compositions). However, due to potential tampering concerns, hard gelatin capsules are no longer a preferred delivery system for consumer (over-the-counter) pharmaceuticals, dietary supplements, or other such products. Additionally, the properties of an ideal composition into which steel pins are to be dipped then dried to form hard capsule shells thereon are not necessarily the same as those for dipping tablets to form a coating thereon. For example, relevant physical properties such as viscosity, weight-gain, film thickness, tensile strength, elasticity, and moisture content will differ between compositions for hard capsule formation and for coating tablets. See e.g., U.S. Pat. No. 1,787,777 (Optimal temperatures of the substrate and coating solution, residence times in the solution, and drying conditions differ.) One disadvantage associated with dipping tablets or capsules into a non-gelatin coating system is that the resulting coatings often lack adequate tensile strength, plasticity, hardness, and thickness. Moreover, the inclusion of plasticizers into such non-gelatin coating systems often results in tablets having soft, tacky coatings without a hardness sufficient to maintain their shape or smoothness during handling. In addition, many non-gelatin compositions do not adhere to the tablet substrate in an amount sufficient to uniformly cover the tablet after a single dipping. Further, many non-gelatin compositions lack the sufficient rheological properties necessary to maintain uniform color dispersion throughout the dipping and drying process. Although attempts have been made to improve the rheological properties of these compositions by, for example, increasing their solids content in order to increase viscosity. However, such compositions often disadvantageously resulted in undesirable coating aesthetics such as surface roughness, decreased gloss, and non-uniform coating thickness. [0008]
  • It is desirable to find a dip coating material, which not only produces a similar elegant, shiny, high gloss, consumer-preferred dosage form similar to that of gelatin-coated forms, but which is absent the limitations of gelatin, particularly those noted above. [0009]
  • SUMMARY OF THE INVENTION
  • The present invention provides for a film forming composition for dip coating a substrate comprising, consisting of, and/or consisting essentially of: [0010]
  • a) hydroxypropylmethyl cellulose; and [0011]
  • b) a thickener selected from the group consisting of xanthan gum, carrageenan, and mixtures thereof, [0012]
  • wherein the composition possesses a surface gloss of at least 150 when applied via dip coating to a substrate. [0013]
  • Another embodiment of the present invention is directed to a water soluble composition for dip-coating a substrate comprising, consisting of, and/or consisting essentially of: [0014]
  • a) hydroxypropylmethyl cellulose; and [0015]
  • b) castor oil, [0016]
  • wherein the composition possesses a surface gloss of at least 150 when applied via dip coating to a substrate. [0017]
  • Another embodiment of the present invention is directed to a water soluble composition for dip-coating a substrate comprising, consisting of, and/or consisting essentially of: [0018]
  • a) hydroxypropylmethyl cellulose; and [0019]
  • b) maltodextrin, [0020]
  • wherein the composition possesses a surface gloss of at least 150 when applied via dip coating to a substrate. [0021]
  • We have found that when a dosage form is coated with the composition of the present invention, the result is an elegant, shiny, high gloss, consumer-preferred dosage form similar to that of a gelatin-coated form, but which lacks the limitations associated with gelatin, particularly those noted above. We have also found that when such a composition is used in dip coating and spray coating operations, it does not inhibit the dissolution of the active coated therewith. Further, we have found that the color uniformity of dosage forms coated with such compositions is improved upon the addition of a weight gain enhancer thereto. [0022]
  • DETAILED DESCRIPTION OF THE INVENTION
  • As used herein, “capsules” refer to hard shell compartments that enclose a dosable ingredient. “Tablets,” as used herein, refer to compressed or molded solid dosage forms of any shape or size. “Caplets,” as used herein, refer to solid, oblong-shaped tablets. “Gelcaps” refer to solid caplets having a glossy gelatinous coating, and “geltabs” refer to solid tablets having flat sides, convex opposing faces, and a glossy gelatinous coating. “Hardness” as used herein in connection with films or coatings indicates the resistance of the film/coating to deformation upon impact. “Water soluble,” as used herein in connection with non-polymeric materials, shall mean from sparingly soluble to very soluble, i.e., not more than 100 parts water required to dissolve 1 part of the non-polymeric, water soluble solute. See Remington, “The Science and Practice of Pharmacy,” pages 208-209 (2000). “Water soluble,” as used herein in connection with polymeric materials, shall mean that the polymer swells in water and can be dispersed at the molecular level to form a homogeneous dispersion or colloidal “solution.” “Surface gloss” as used herein, shall refer to amount of light reflectance as measured at a 60 degree incident angle using the method set forth in Example 7 herein. [0023]
  • Dimethicone is a well known pharmaceutical material consisting of linear siloxane polymers containing repeating units of the formula {—(CH[0024] 2)2SiO}n stabilized with trimethylsiloxy end blocking units of the formula [(CH3)3SiO-]. Simethicone is the mixture of dimethicone and silicon dioxide. For the purposes of this invention, the two materials may be used interchangably.
  • The first embodiment of this invention is directed to water soluble, substantially gelatin-free, film forming compositions for dip coating tablets or manufacturing capsules via a dip molding process. One composition comprises, consists of, and/or consists essentially of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; and a thickener, such as a hydrocolloid, e.g., xanthan gum or carrageenan. In another embodiment, the composition comprises, consists of, and/or consists essentially of a film former such as a modified starch selected from waxy maize starch, tapioca dextrin, and derivatives and mixtures thereof; a thickener selected from sucrose, dextrose, fructose, maltodextrin, polydextrose, and derivatives and mixtures thereof; and a plasticizer, e.g., polyethylene glycol, propylene glycol, vegetable oils such as castor oil, glycerin, and mixtures thereof. In yet another embodiment, the composition comprises, consists of, and/or consists essentially of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; and optionally a plasticizer, such as vegetable oils, e.g., castor oil; and may optionally be substantially free of thickeners such as hydrocolloids, e.g. xanthan gum. In yet another embodiment, the composition comprises, consists of, and/or consists essentially of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; an extender, such as polycarbohydrates, e.g. maltodextrin; and optionally a plasticizer, such as glycols, e.g., polyethylene glycol; and may optionally be substantially free of thickeners such as hydrocolloids, e.g. xanthan gum. As used herein, “substantially gelatin-free” shall mean less than about 1 percent, e.g. less than about 0.5 percent, of gelatin in the composition, and “substantially free of thickeners” shall mean less than about 1 percent, e.g. less than about 0.01 percent, of thickeners in the composition. [0025]
  • Any film former known in the art is suitable for use in film forming composition of the present invention. Examples of suitable film formers include, but are not limited to, polyvinylalcohol (PVA), hydroxypropyl starch, hydroxyethyl starch, pullulan, methylethyl starch, carboxymethyl starch, methylcellulose, hydroxypropylcellulose (HPC), hydroxyethylmethylcellulose (HEMC), hydroxypropylmethylcellulose (HPMC), hydroxybutylmethylcellulose (HBMC), hydroxyethylethylcellulose (HEEC), hydroxyethylhydroxypropylmethyl cellulose (HEMPMC), pre-gelatinized starches, and polymers and derivatives and mixtures thereof. [0026]
  • One suitable hydroxypropylmethylcellulose compound is “HPMC 2910”, which is a cellulose ether having a degree of substitution of about 1.9 and a hydroxypropyl molar substitution of 0.23, and containing, based upon the total weight of the compound, from about 29% to about 30% methoxyl and from about 7% to about 12% hydroxylpropyl groups. HPMC 2910 is commercially available from the Dow Chemical Company under the tradename, “Methocel E.” “Methocel E5,” which is one grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 4 to 6 cps (4 to 6 millipascal-seconds) at 20° C. in a 2% aqueous solution as determined by a Ubbelohde viscometer. Similarly, “Methocel E6,” which is another grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 5 to 7 cps (5 to 7 millipascal-seconds) at 20° C. in a 2% aqueous solution as determined by a Ubbelohde viscometer. “Methocel E15,” which is another grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 15000 cps (15 millipascal-seconds) at 20° C. in a 2% aqueous solution as determined by a Ubbelohde viscometer. As used herein, “degree of substitution” shall mean the average number of substituent groups attached to a anhydroglucose ring, and “hydroxypropyl molar substitution” shall mean the number of moles of hydroxypropyl per mole anhydroglucose. [0027]
  • As used herein, “modified starches” include starches that have been modified by crosslinking, chemically modified for improved stability, or physically modified for improved solubility properties. As used herein, “pre-gelatinized starches” or “instantized starches” refers to modified starches that have been pre-wetted, then dried to enhance their cold-water solubility. Suitable modified starches are commercially available from several suppliers such as, for example, A. E. Staley Manufacturing Company, and National Starch & Chemical Company. One suitable modified starch includes the pre-gelatinized waxy maize derivative starches that are commercially available from National Starch & Chemical Company under the tradenames, “Purity Gum” and “FilmSet”, and derivatives, copolymers, and mixtures thereof. Such waxy maize starches typically contain, based upon the total weight of the starch, from about 0 percent to about 18 percent of amylose and from about 100 percent to about 88 percent of amylopectin. [0028]
  • Suitable tapioca dextrins include those available from National Starch & Chemical Company under the tradename, “Crystal Gum” or “K-4484,” and derivatives thereof such as modified food starch derived from tapioca, which is available from National Starch and Chemical under the tradename, “Purity Gum 40,” and copolymers and mixtures thereof. [0029]
  • Any thickener known in the art is suitable for use in the film forming composition of the present invention. Examples of such thickeners include but are not limited to hydrocolloids such as alginates, agar, guar gum, locust bean, carrageenan, tara, gum arabic, tragacanth, pectin, xanthan, gellan, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan, and derivatives and mixtures thereof. Additional suitable thickeners include sucrose, dextrose, fructose, maltodextrin, polydextrose, and the like, and derivatives and combinations thereof. [0030]
  • Suitable xanthan gums include those available from C. P. Kelco Company under the tradename, “Keltrol 1000,” “Xantrol 180,” or “K9B310.”[0031]
  • Any plasticizer known in the pharmaceutical art is suitable for use in the present invention, and may include, but not be limited to polyethylene glycol; glycerin; sorbitol; triethyl citrate; tribuyl citrate; dibutyl sebecate; vegetable oils such as castor oil; surfactants such as polysorbates, sodium lauryl sulfates, and dioctyl-sodium sulfosuccinates; propylene glycol; mono acetate of glycerol; diacetate of glycerol; triacetate of glycerol; natural gums and mixtures thereof. In solutions containing a cellulose ether film former, an optional plasticizer may be present in an amount, based upon the total weight of the solution, from about 0 percent to about 40 percent. [0032]
  • In one embodiment, the film forming composition for dip coating substrates may be substantially free of gelatin, i.e., e.g. contains less than about 1%, or less than about 0.01% of gelatin. [0033]
  • In another embodiment, the film forming composition for dip coating substrates may be substantially free of bovine derived materials, i.e., e.g. contains less than about 1%, or less than about 0.01% of bovine derived materials. [0034]
  • In embodiments wherein a cellulose ether film former is used in the composition, the film forming composition for dip coating substrates may be substantially free of hydrocolloids, i.e., e.g. contains less than about 1%, or less than about 0.01% of hydrocolloids. [0035]
  • In yet another embodiment, the film forming composition for dip coating substrates may be substantially free of plasticizers, i.e., e.g. contains less than about 1%, or less than about 0.01% of plasticizers. [0036]
  • In one embodiment, the film forming composition for dip coating substrates contains, based upon the total dry solids weight of the composition, from about 95 percent to less than about 100 percent, e.g. from about 95 percent to about 99.5 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; and from about 0.5 percent to about 5 percent of a thickener such as a hydrocolloid, e.g., xanthan gum. [0037]
  • In another embodiment, the film forming composition for dip coating substrates contains, based upon the total dry solids weight of the composition, from about 40 percent to about 60 percent, e.g. from about 50 percent to about 55 percent, of a modified starch, e.g. a waxy maize starch, a tapioca dextrin, and/or mixtures and derivatives thereof; from about 15 percent to about 30 percent, e.g., from about 20 percent to about 25 percent of a plasticizer, e.g., glycerin, polyethylene glycol, propylene glycol, castor oil, and mixtures thereof; and from about 5 percent to about 25 percent, e.g., from about 10 percent to about 20 percent, of a thickener, e.g., sucrose, dextrose, fructose, maltodextrin, polydextrose, and mixtures thereof. [0038]
  • In yet another embodiment, the film forming composition for dip coating substrates contains, based upon the total dry solids weight of the composition, from about 95 percent to about 100 percent, e.g. from about 97 percent to about 100 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose. [0039]
  • In yet another embodiment, the film forming composition for dip coating substrates contains, based upon the total dry solids weight of the composition, from about 95 percent to about 100 percent, e.g. from about 97 percent to about 100 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose, and is substantially free of hydrocolloids, i.e., e.g. contains less than about 1%, or less than about 0.01% of hydrocolloids. [0040]
  • In yet another embodiment, the film forming composition for dip coating substrates contains, based upon the total dry solids weight of the composition, from about 95 percent to about 100 percent, e.g. from about 97 percent to about 100 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; and from about 0.1 percent to about 1.0 percent, e.g. from about 0.25 percent to about 0.5 percent of a plasticizer such as vegetable oils, e.g. Castor Oil. [0041]
  • In yet another embodiment, the film forming composition for dip coating substrates contains, based upon the total dry solids weight of the composition, from about 5 percent to about 99 percent, e.g. from about 50 percent to about 90 percent, or from about 80 percent to about 90 percent of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; from about 1 percent to about 80 percent, e.g. from about 5 percent to about 50 percent or from about 5 percent to about 40 percent of an extender, such as polycarbohydrates, e.g. maltodextrin; and from about 0.1 percent to about 20 percent, e.g. from about 2.5 percent to about 15 percent of a plasticizer such as glycols, e.g. polyethylene glycol. Examples of suitable dry compositions are disclosed in, for example, U.S. Pat. Nos. 5,470,581 and 6,183,808, which are incorporated by reference herein. [0042]
  • These film forming compositions are typically in the form of a dispersion for ease of dip coating substrates therein. Such dispersions contain a solvent in an amount, based upon the total weight of the dispersion, from about 30 percent to about 97 percent, for example, from about 80 percent to about 92 percent or from about 40 percent to about 75 percent. Examples of suitable solvents include, but are not limited to water; alcohols such as methanol, ethanol, and isopropanol; organic solvents such as methylene chloride, acetone, and the like; and mixtures thereof. In one embodiment, the solvent is water. The resulting film forming dispersion typically possesses a solids level of, based upon the total weight of the film forming dispersion, from about 3 percent to about 70 percent, for example, from about 8 percent to about 20 percent or from about 25 percent to about 60 percent. [0043]
  • In one embodiment, the film forming composition for dip coating substrates contains, based upon the total wet weight of the dipping dispersion composition, from about 5 percent to about 20 percent, e.g. from about 8 percent to about 15 percent or from about 10 percent to about 14 percent, of a film former such as hydroxypropylmethylcellulose and from about 0.05 percent to about 0.2 percent, e.g. from about 0.08 percent to about 0.16 percent or from about 0.1 percent to about 0.14 percent, of a thickener such as xanthan gum. [0044]
  • In another embodiment, the film forming composition for dip coating substrates contains, based upon the total wet weight of the dipping dispersion composition, from about 20 percent to about 35 percent, e.g. from about 25 percent to about 30 percent, of a film former such as waxy maize starch, tapioca dextrin, and/or derivatives and mixtures thereof; from about 5 percent to about 20 percent, e.g., from about 10 percent to about 15 percent of a plasticizer such as glycerin, polyethylene glycol, propylene glycol, castor oil, and mixtures thereof; and from about 5 percent to about 15 percent of a thickener selected from sucrose, fructose, dextrose, maltodextrin, polydextrose, and mixtures thereof. [0045]
  • In yet another embodiment, the film forming composition for dip coating substrates contains, based upon the total wet weight of the dipping dispersion composition, from about 5 percent to about 25 percent, e.g. from about 8 percent to about 20 percent or from about 10 to about 16 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose. [0046]
  • In yet another embodiment, the film forming composition for dip coating substrates contains, based upon the total wet weight of the dipping dispersion composition, from about 5 percent to about 25 percent, e.g. from about 8 percent to about 20 percent or from about 10 to about 16 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose, and is substantially free of hydrocolloids, i.e., e.g. contains less than about 1%, or less than about 0.01% of hydrocolloids. [0047]
  • In yet another embodiment, the film forming composition for dip coating substrates contains, based upon the total wet weight of the dipping dispersion composition, from about 5 percent to about 25 percent, e.g. from about 8 percent to about 20 percent or from about 10 to about 16 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; and from about 0.001 percent to about 0.1 percent, e.g. from about 0.01 percent to about 0.09 percent of a plasticizer such as vegetable oils, e.g. castor oil. [0048]
  • In yet another embodiment, the film forming composition for dip coating substrates contains, based upon the total wet weight of the dipping dispersion composition, from about 1 percent to about 21 percent, e.g. from about 10 percent to about 19 percent or from about 16 percent to about 19 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; from about 0.1 percent to about 17 percent, e.g. from about 1 percent to about 11 percent or from about 1 percent to about 8 percent of an extender, such as polycarbohydrates, e.g. maltodextrin; and from about 0.02 percent to about 4 percent, e.g. from about 0.5 percent to about 3 percent of a plasticizer such as glycols, e.g. polyethylene glycol. [0049]
  • Optionally, the composition for dipping may further comprise other ingredients such as, based upon the total weight of the dipping solution, from about 0 percent to about 2 percent preservatives such as methylparaben and propylparaben, from about 0 percent to about 14 percent opacifying agents such as titanium dioxide, and/or from about 0 percent to about 14 percent colorants. See Remington's Practice of Pharmacy, Martin & Cook, 17th ed., pp. 1625-30, which is herein incorporated by reference. [0050]
  • Any coloring agent suitable for use in pharmaceutical applications may be used in the present invention and may include, but not be limited to azo dyes, quinopthalone dyes, triphenylmethane dyes, xanthene dyes, indigoid dyes, iron oxides, iron hydroxides, titanium dioxide, natural dyes, and mixtures thereof. More specifically, suitable colorants include, but are not limited to patent blue V, acid brilliant green BS, red 2G, azorubine, ponceau 4R, amaranth, D&C red 33, D+C red 22, D+C red 26, D+C red 28, D+C yellow 10, FD+C yellow 5, FD+C yellow 6, FD+C red 3, FD+C red 40, FD+C blue 1, FD+C blue 2, FD+C green 3, brilliant black BN, carbon black, iron oxide black, iron oxide red, iron oxide yellow, titanium dioxide, riboflavin, carotenes, antyhocyanines, turmeric, cochineal extract, clorophyllin, canthaxanthin, caramel, betan in, and mixtures thereof. [0051]
  • In one embodiment, each end of the tablet or capsule may be coated with dip coatings of different colors to provide a distinctive appearance for specialty products. See U.S. Pat. No. 4,820,524, which is incorporated by reference herein. [0052]
  • In one embodiment, the pharmaceutical dosage form is comprised of a) a core containing an active ingredient; b) an optional first coating layer comprised of a subcoating that substantially covers the core; and c) a second coating layer on the surface of the first coating layer, the second coating layer comprised of the dip coating composition of the present invention. As used herein, “substantially covers” shall mean at least about 95 percent of the surface area of the core is covered by the subcoating. [0053]
  • In an alternate embodiment, a first active ingredient may be contained in the first coating layer, and the core may contain a second active ingredient and/or an additional amount of the first active ingredient. In yet another embodiment, the active ingredient may be contained in the first coating layer, and the core may be substantially free, i.e., less than about 1 percent, e.g. less than about 0.1 percent, of active ingredient. [0054]
  • The use of subcoatings is well known in the art and disclosed in, for example, U.S. Pat. Nos. 3,185,626, which is incorporated by reference herein. Any composition suitable for film-coating a tablet may be used as a subcoating according to the present invention. Examples of suitable subcoatings are disclosed in U.S. Pat. Nos. 4,683,256, 4,543,370, 4,643,894, 4,828,841, 4,725,441, 4,802,924, 5,630,871, and 6,274,162, which are all incorporated by reference herein. Additional suitable subcoatings include one or more of the following ingredients: cellulose ethers such as hydroxypropylmethylcellulose, hydroxypropylcellulose, and hydroxyethylcellulose; polycarbohydrates such as xanthan gum, starch, and maltodextrin; plasticizers including for example, glycerin, polyethylene glycol, propylene glycol, dibutyl sebecate, triethyl citrate, vegetable oils such as castor oil, surfactants such as polysorbate-80, sodium lauryl sulfate and dioctyl-sodium sulfosuccinate; polycarbohydrates, pigments, and opacifiers. [0055]
  • In one embodiment, the subcoating may be comprised of, based upon the total weight of the subcoating, from about 2 percent to about 8 percent, e.g. from about 4 percent to about 6 percent of a water-soluble cellulose ether and from about 0.1 percent to about 1 percent, castor oil, as disclosed in detail in U.S. Pat. No. 5,658, 589, which is incorporated by reference herein. In another embodiment, the subcoating may be comprised of, based upon the total weight of the subcoating, from about 20 percent to about 50 percent, e.g., from about 25 percent to about 40 percent of HPMC; from about 45 percent to about 75 percent, e.g., from about 50 percent to about 70 percent of maltodextrin; and from about 1 percent to about 10 percent, e.g., from about 5 percent to about 10 percent of PEG 400. [0056]
  • The dried subcoating typically is present in an amount, based upon the dry weight of the core, from about 0 percent to about 5 percent. The dried dip coating layer typically is present in an amount, based upon the dry weight of the core and the optional subcoating, from about 1.5 percent to about 10 percent. [0057]
  • The average thickness of the dried dip coating layer typically is from about 40 to about 400 microns. However, one skilled in the art would readily appreciate without undue experimentation that the dip coating thickness may be varied in order to provide a smoother, easier to swallow, dosage form or to achieve a desired dissolution profile. Moreover, the thickness of dipped film coatings may vary at different locations on the substrate depending upon its shape. For example, the thickness of the coating at an edge or corner of a substrate may be as much as 50 percent to 70 percent less than the thickness of the coating at the center of a major face of the substrate. This difference can be minimized by, for example, use of a thicker subcoating, or use of dipping compositions that result in higher weight gains on the substrate. [0058]
  • In embodiments wherein a thicker dip coating is desired, we have found that an effective amount of a weight gain enhancer selected from the group consisting of simethicone, polysorbate 80 and mixtures thereof, may be added to a film forming composition comprised, consisting of, and/or consisting essentially of a film former and an optional thickener such as a hydrocolloid. The weight gain enhancer is used in an amount sufficient to increase the weight gain of the coating solution, e.g. by at least about 10 percent, by at least about 20%, or by at least about 30% on a substrate when dried. The percent weight gain increase is determined based upon the difference between the total weight of the coated substrate with the coating composition including the weight gain enhancer, and the total weight of an coated equivalent substrate, which has been coated under similar processing conditions with a coating composition that does not include an effective amount of weight gain enhancer. [0059]
  • In one embodiment, the film former is a cellulose ether such as HPMC, and the thickener is a hydrocolloid such as xanthan gum and the weight gain enhancer is simethicone. [0060]
  • A suitable film forming composition capable of achieving increased weight gain of dip coating on a substrate may contain, based upon the total dry weight of the film forming composition, from about 40 percent to about 99.9 percent, e.g. from about 95 percent to about 99.5 percent, or from about 40 percent to about 60 percent of a film former; from about 0 percent to about 60 percent , e.g. from about 0 percent to about 10 percent, or from about 0.5 percent to about 5 percent, or from about 10 percent to about 25 percent of a thickener; and from about 0.01 percent to about 0.25 percent, e.g. from about 0.03 percent to about 0.15 percent of a weight gain enhancer. When aesthetics of the final tablet are of particular concern, it is recommended to not use greater than about 0.25 percent of a weight gain enhancer. As shown above, the amount of thickener suitable for use in the composition will vary depending upon, for example, the particular thickener selected and the desired properties of the coating. For example, when xanthan gum is the thickener of choice, the amount of xanthan gum thickener may range, based upon the total dry weight of the film forming composition, from about 0.5 percent to about 5 percent. [0061]
  • The film forming compositions of the present invention may be prepared by combining the film former, the thickener, and any optional ingredients such as plasticizers, preservatives, colorants, opacifiers, the weight gain enhancer, or other ingredients with the solventusing a high shear mixer until homogeneous under ambient conditions. In embodiments wherein a waxy maize starch derivative is used as a film former, the mixture may be heated to a temperature of about 60° C. to about 90° C. for faster dispersion of the ingredients. Alternatively, the film former and thickener may be preblended as dry powders, followed by addition of the resulting powder blend to the water and optional weight gain enhancer with high speed mixing. In order to remove substantially all of the bubbles from the resulting mixture, the pressure may then be decreased to about 5 inches Hg while reducing the mixing speed in order to avoid creating a vortex therein. Any other additional optional ingredients may then be added thereto at constant mixing. [0062]
  • It has surprisingly been found that substrates may be dipped into such solutions of the present invention using the same equipment and similar range of process conditions as used for the production of dip molded, gelatin-coated tablets. For example, both tablets and hard capsules may be coated using the aqueous dispersions of the present invention via known gelatin-dipping process parameters and equipment. Details of such equipment and processing conditions are known in the art and are disclosed at, for example, U.S. Pat. No. 4,820,524, which is incorporated by reference herein. Advantageously, because the coating solutions of the present invention are fluid at room temperature and are less susceptible to microbial growth than gelatin compositions, the dip coating process may occur under ambient temperature and pressure conditions. [0063]
  • The tablets dip coated with the composition of the present invention may contain one or more active agents. The term “active agent” is used herein in a broad sense and may encompass any material that can be carried by or entrained in the system. For example, the active agent can be a pharmaceutical, nutraceutical, vitamin, dietary supplement, nutrient, herb, foodstuff, dyestuff, nutritional, mineral, supplement, or favoring agent or the like and combinations thereof. [0064]
  • The active agents useful herein can be selected from classes from those in the following therapeutic categories: ace-inhibitors; alkaloids; antacids; analgesics; anabolic agents; anti-anginal drugs; anti-allergy agents; anti-arrhythmia agents; antiasthmatics; antibiotics; anticholesterolemics; anticonvulsants; anticoagulants; antidepressants; antidiarrheal preparations; anti-emetics; antihistamines; antihypertensives; anti-infectives; anti-inflammatories; antilipid agents; antimanics; anti-migraine agents; antinauseants; antipsychotics; antistroke agents; antithyroid preparations; anabolic drugs; antiobesity agents; antiparasitics; antipsychotics; antipyretics; antispasmodics; antithrombotics; antitumor agents; antitussives; antiulcer agents; anti-uricemic agents; anxiolytic agents; appetite stimulants; appetite suppressants; beta-blocking agents; bronchodilators; cardiovascular agents; cerebral dilators; chelating agents; cholecystekinin antagonists; chemotherapeutic agents; cognition activators; contraceptives; coronary dilators; cough suppressants; decongestants; deodorants; dermatological agents; diabetes agents; diuretics; emollients; enzymes; erythropoietic drugs; expectorants; fertility agents; fungicides; gastrointestinal agents; growth regulators; hormone replacement agents; hyperglycemic agents; hypoglycemic agents; ion-exchange resins; laxatives; migraine treatments; mineral supplements; mucolytics, narcotics; neuroleptics; neuromuscular drugs; non-steroidal anti-inflammatories (NSAIDs); nutritional additives; peripheral vasodilators; polypeptides; prostaglandins; psychotropics; renin inhibitors; respiratory stimulants; sedatives; steroids; stimulants; sympatholytics; thyroid preparations; tranquilizers; uterine relaxants; vaginal preparations; vasoconstrictors; vasodilators; vertigo agents; vitamins; wound healing agents; and others. [0065]
  • Active agents that may be used in the invention include, but are not limited to: acetaminophen; acetic acid; acetylsalicylic acid, including its buffered forms; acrivastine; albuterol and its sulfate; alcohol; alkaline phosphatase; allantoin; aloe; aluminum acetate, carbonate, chlorohydrate and hydroxide; alprozolam; amino acids; aminobenzoic acid; amoxicillin; ampicillin; amsacrine; amsalog; anethole; ascorbic acid; aspartame; astemizole; atenolol; azatidine and its maleate; bacitracin; balsam peru; BCNU (carmustine); beclomethasone diproprionate; benzocaine; benzoic acid; benzophenones; benzoyl peroxide; benzquinamide and its hydrochloride; bethanechol; biotin; bisacodyl; bismuth subsalicylate; bornyl acetate; bromopheniramine and its maleate; buspirone; caffeine; calamine; calcium carbonate, casinate and hydroxide; camphor; captopril; cascara sagrada; castor oil; cefaclor; cefadroxil; cephalexin; centrizine and its hydrochloride; cetirizine; cetyl alcohol; cetylpyridinium chloride; chelated minerals; chloramphenicol; chlorcyclizine hydrochloride; chlorhexidine gluconate; chloroxylenol; chloropentostatin; chlorpheniramine and its maleates and tannates; chlorpromazine; cholestyramine resin; choline bitartrate; chondrogenic stimulating protein; cimetidine; cinnamedrine hydrochloride; citalopram; citric acid; clarithromycin; clemastine and its fumarate; clonidine; clorfibrate; cocoa butter; cod liver oil; codeine and its fumarate and phosphate; cortisone acetate; ciprofloxacin HCI; cyanocobalamin; cyclizine hydrochloride; cyproheptadine; danthron; dexbromopheniramine maleate; dextromethorphan and its hydrohalides; diazepam; dibucaine; dichloralphenazone; diclofen and its alkali metal sales; diclofenac sodium; digoxin; dihydroergotamine and its hydrogenates/mesylates; diltiazem; dimethicone; dioxybenzone; diphenhydramine and its citrate; diphenhydramine and its hydrochloride; divalproex and its alkali metal salts; docusate calcium, potassium, and sodium; doxycycline hydrate; doxylamine succinate; dronabinol; efaroxan; enalapril; enoxacin; ergotamine and its tartrate; erythromycin; estropipate; ethinyl estradiol; ephedrine; epinephrine bitartrate; erythropoietin; eucalyptol; famotidine; fenoprofen and its metal salts; ferrous fumarate, gluconate and sulfate; fexofenadine; fluoxetine; folic acid; fosphenytoin; 5-fluorouracil (5-FU); fluoxetine; flurbiprofen; furosemide; gabapentan; gentamicin; gemfibrozil; glipizide; glycerine; glyceryl stearate; granisetron; griseofulvin; growth hormone; guafenesin; hexylresorcinol; hydrochlorothiazide; hydrocodone and its tartrates; hydrocortisone and its acetate; 8-hydroxyquinoline sulfate; hydroxyzine and its pamoate and hydrochloride salts; ibuprofen; indomethacin; inositol; insulin; iodine; ipecac; iron; isosorbide and its mono- and dinitrates; isoxicam; ketamine; kaolin; ketoprofen; lactic acid; lanolin; lecithin; leuprolide acetate; lidocaine and its hydrochloride salt; lifinopril; liotrix; loperamide, loratadine; lovastatin; luteinizing hormore; LHRH (lutenizing hormone replacement hormone); magnesium carbonate, hydroxide, salicylate, and trisilicate; meclizine; mefenamic acid; meclofenamic acid; meclofenamate sodium; medroxyprogesterone acetate; methenamine mandelate; menthol; meperidine hydrochloride; metaproterenol sulfate; methscopolamine and its nitrates; methsergide and its maleate; methyl nicotinate; methyl salicylate; methyl cellulose; methsuximide; metoclopramide and its halides/hydrates; metronidazole; metoprotol tartrate; miconazole nitrate; mineral oil; minoxidil; morphine; naproxen and its alkali metal sodium salts; nifedipine; neomycin sulfate; niacin; niacinamide; nicotine; nicotinamide; nimesulide; nitroglycerine; nonoxynol-9; norethindrone and its acetate; nystatin; octoxynol; octoxynol-9; octyl dimethyl PABA; octyl methoxycinnamate; omega-3 polyunsaturated fatty acids; omeprazole; ondansetron and its hydrochloride; oxolinic acid; oxybenzone; oxtriphylline; para-aminobenzoic acid (PABA); padimate-O; paramethadione; pentastatin; peppermint oil; pentaerythritol tetranitrate; pentobarbital sodium; perphenazine; pheneizine sulfate; phenindamine and its tartrate; pheniramine maleate; phenobarbital; phenol; phenolphthalein; phenylephrine and its tannates and hydrochlorides; phenylpropanolamine; phenytoin; pirmenol; piroxicam and its salts; polymicin B sulfate; potassium chloride and nitrate; prazepam; procainamide hydrochloride; procaterol; promethazine and its hydrochloride; propoxyphene and its hydrochloride and napsylate; pramiracetin; pramoxine and its hydrochloride salt; prochlorperazine and its maleate; propanolol and its hydrochloride; promethazine and its hydrochloride; propanolol; pseudoephedrine and its sulfates and hydrochlorides; pyridoxine; pyrolamine and its hydrochlorides and tannates; quinapril; quinidine gluconate and sulfate; quinestrol; ralitoline; ranitadine; resorcinol; riboflavin; salicylic acid; scopolamine; sesame oil; shark liver oil; simethicone; sodium bicarbonate, citrate, and fluoride; sodium monofluorophosphate; sucralfate; sulfanethoxazole; sulfasalazine; sulfur; sumatriptan and its succinate; tacrine and its hydrochloride; theophylline; terfenadine; thiethylperazine and its maleate; timolol and its maleate; thioperidone; tramadol; trimetrexate; triazolam; tretinoin; tetracycline hydrochloride; tolmetin; tolnaftate; triclosan; trimethobenzamide and its hydrochloride; tripelennamine and its hydrochloride; tripolidine hydrochloride; undecylenic acid; vancomycin; verapamil HCI; vidaribine phosphate; vitamins A, B, C, D, B[0066] 1, B2, B6, B12, E, and K; witch hazel; xylometazoline hydrochloride; zinc; zinc sulfate; zinc undecylenate. Active agents may further include, but are not limited to food acids; insoluble metal and mineral hydroxides, carbonates, oxides, polycarbophils, and salts thereof; adsorbates of active drugs on a magnesium trisilicate base and on a magnesium aluminum silicate base, and mixtures thereof. Mixtures and pharmaceutically acceptable salts of these and other actives can be used.
  • In one embodiment, the dosage forms coated with the dip coatings of the present invention provided for immediate release of the active ingredient, i.e. the dissolution of the dosage form conformed to USP specifications for immediate release tablets containing the particular active ingredient employed. For example, for acetaminophen tablets, U.S. Pat. No. 24 specifies that in pH 5.8 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the acetaminophen contained in the dosage form is released therefrom within 30 minutes after dosing, and for ibuprofen tablets, U.S. Pat. No. 24 specifies that in pH 7.2 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the ibuprofen contained in the dosage form is released therefrom within 60 minutes after dosing. See U.S. Pat. No. 24, 2000 Version, 19-20 and 856 (1999). [0067]
  • We have unexpectedly found that the coatings formed by dipping substrates into the compositions of the present invention possessed excellent properties comparable to those possessed by gelatin coatings, e.g. crack resistance, hardness, thickness, color uniformity, smoothness, and gloss. Typically, the coatings of the present invention possessed a surface gloss of greater than about 150, e.g. greater than about 190 or greater than about 210 when measured according to the method set forth in example 7 herein. [0068]
  • In addition, tablets dip coated with the compositions of the present invention were superior to tablets dip coated with conventional gelatin-based coatings in several important ways. First, tablets dip coated with the compositions of the present invention advantageously retained acceptable dissolution characteristics for the desired shelf-life and storage period at elevated temperature and humidity conditions. In particular, thehe cellulose-ether based compositions according to the present invention were also advantageously more resistant to microbial growth, which thereby enabled a longer shelf-life or use-life of the dipping solution as well as a reduction in manufacturing cost. Second, the sugar-thickened dipping dispersions according to the present invention beneficially employed a lower water content relative to that of gelatin-containing dispersions, which thereby enabled a shorter drying cycle time. Although the water content of the other dipping dispersions of the present invention may have been higher than that typically found in gelatin-based dipping solutions, the cellulose-ether based compositions of the present invention surprisingly required a shorter drying cycle time relative to that for gelatin-containing compositions. Third, the dried coatings comprised of the compositions of the present invention also surprisingly and advantageously contained fewer air bubbles relative to the amount present in dried, gelatin based dipping compositions. Fourth, unlike dip processing with gelatin-containing compositions, substrates may optionally be dipped in the solutions of the present invention at room temperature, which is economically more beneficial. Fifth, the dip coated compositions of the present invention possessed a higher degree of glossiness relative to similar coatings applied via spray coating methods known in the art. The dip coated compositions of the present invention also possessed a similar degree of glossiness relative to that possessed by gelatin-containing dip or enrobing coatings, which are currently viewed as the industry benchmark for high gloss coatings. See, e.g., U.S. Pat. No.6,274,162 (Typical gloss readings for standard, commercially available gel-dipped or gelatin enrobed tablets range from about 200 to 240 gloss units, gloss readings for standard, commercialy available sugar-coated medicaments range from 177 to 209 gloss units, and gloss readings for a new, high-gloss coating system range from about 148 to about 243 gloss units.). [0069]
  • We have further unexpectedly found that the addition of an effective amount of weight gain enhancer to a film forming composition comprised of film former and hydrocolloid not only significantly increased the resulting dry weight of the dip coating on a substrate, but it also improved the color uniformity of the coating. [0070]
  • The invention illustratively disclosed herein suitably may be practiced in the absence of any component, ingredient, or step which is not specifically disclosed herein. Several examples are set forth below to further illustrate the nature of the invention and the manner of carrying it out. However, the invention should not be considered as being limited to the details thereof.[0071]
  • EXAMPLES Example 1
  • Preparation of Subcoating Dispersions [0072]
  • An aqueous dispersion containing the ingredients set forth in Table A was prepared by combining all of the ingredients in a beaker under ambient conditions. [0073]
    TABLE A
    Aqueous Dispersion Subcoating Composition
    Ingredient Part*
    HPMC (2910, 5 mPs) from  20
    Dow Chemical Company under the tradename,
    “Methocel E-5”
    Castor oil  1
    Water 241.5
    Total Coating Solution 262.5
    % solids in coating solution  8%
  • [0074]
    TABLE B
    Aqueous Dispersion Subcoating Compositions
    Ingredient Ex 1A** Ex 1B Ex 1C Ex 1D Ex 1E
    HPMC 2910, 5  20  40  40  28  28
    mPs
    Castor oil  1  0  0  0  0
    water 212.3 566.67 566.67 566.67 566.67
    maltodextrin  0  53  53  67  67
    PEG 400  0  7  7  5  5
    Hydroxy-  0  0  0  0  0
    ethylcellulose*
    Total coating 233.3 666.67 666.67 666.67 666.67
    solution
    Wt % solids in  9%  15%  15  15  15
    coating
    solution
  • [0075]
    TABLE C
    Aqueous Dispersion Subcoating Compositions
    Ingredient Ex 1F** Ex 1G Ex 1H
    water 566.67 566.67 690.4
    maltodextrin  71  71  0
    Castor oil  0  0  0.13
    HPMC (1910,  0  0  32.4
    5 mPas)
    PEG 400  5  5  0
    Hydroxy-  24  24  0
    ethylcellulose*
    Total coating 666.67 666.67 722.9
    solution
    Wt % solids in  15%  15%  4.5%
    coating
    solution
  • Example 2 Preparation of Subcoated Tablets
  • Compressed tablets were prepared in accordance with the procedure set forth in Example 1 of U.S. Pat. No. 5,658,589 (“'589 patent”), which was incorporated by reference herein. [0076]
  • The dispersion of Example 1 was then applied onto the compressed tablets via spraying in accordance with the procedure set forth in the examples of the '589 patent. As shown in Table D below, the dried subcoated tablets possessed an average 2% to 4% weight gain relative to the weight of the subcoating-free tablets. [0077]
  • This process was repeated with additional compressed tablets, but with the substitution of each, respective subcoating dispersion produced in Example 1A to I H for that of Example 1. The percentage weight gain of the dried subcoated tablets are set forth below in Table D: [0078]
    TABLE D
    % Weight Gain of Dried Subcoated Tablets
    Example Number % Weight Gain
    1A 2
    1B 2
    1C 4
    1D 2
    1E 4
    1F 2
    1G 4
    1H 4
  • Example 3 Preparation of HPMC Coated Tablets
  • Aqueous HPMC dipping solutions containing the ingredients set forth in Table E were prepared: [0079]
    TABLE E
    Composition of HPMC Dipping Solutions
    Ingredient Ex 3A* (g) Ex 3B (g) Ex 3C (g) Ex 3D (%) Ex 3E (%) Ex 3F (%)
    HPMC E5 32.5 0 32.5 10 11 14
    Water 200 200 200 89.89 88.879 85.85
    HPMC 0 20 0 0 0
    (2910,
    15 mPs)
    Xanthan 0 0 0 0.11 0.121 0.15
    gum
    PEG 400 0 0 8 0 0 0
    % (wt.) 14 9 17 10.11 11.121 14.15
    solids in
    dipping
    solution
  • Example 3A
  • Preparation Of Dipping Solution of Example 3A: [0080]
  • HPMC was dispersed into 200 ml of deionized water at a temperature of 70° C. After adding about 1 wt % FD&C blue dye thereto, the solution was mixed until homogeneous. The solution was then cooled to a temperature of about 22° C. [0081]
  • Example 3B
  • Preparation of Dipping Solution of Example 3B: [0082]
  • The procedure of Example 3A was repeated, but with substitution of HPMC (2910, 15 mPs) for the HPMC E5. [0083]
  • Example 3C Preparation Of Dipping Solution of Example 3C:
  • HPMC was dispersed into 200 ml of deionized water at a temperature of 70° C. After adding the PEG 400 thereto, the solution was mixed until homogeneous. The solution was then cooled to a temperature of about 22° C. [0084]
  • Example 3D
  • Preparation Of Dipping Solution of Example 3D: [0085]
  • HPMC and xanthan gum were added to purified water at a temperature of 80° C. until the powder was dispersed. After discontinuing the heat, the solution was divided into two parts. 4.35 wt. % of a yellow color dispersion available from Colorcon, Inc. under the tradename, “Opatint Yellow DD-2115” was added to the first part and mixed at a low speed until dispersed. 5.8% of a green color dispersion available from Colorcon, Inc. under the tradename, “Opatint Green DD-11000” was added to the second part and mixed at a low speed until dispersed. The two dispersed solutions were then stored under ambient conditions for about 12 hours. [0086]
  • Example 3E
  • Preparation Of Dipping Solution of Example 3E: [0087]
  • The procedure of Example 3D was repeated, but using the components of Example 3E. [0088]
  • Example 3F
  • Preparation Of Dipping Solution of Example 3F: [0089]
  • The procedure of Example 3D was repeated, but using the components of Example 3F. [0090]
  • Example 3G
  • Preparation of Hand-Dipped Dip Coated Tablets: [0091]
  • The subcoated tablets prepared in accordance with Example 2 using the subcoating produced in Example 1H were hand-dipped into the dipping solutions of Example 3A for a dwell time of 1 second, removed from the dipping solution, then dried under ambient conditions. [0092]
  • This procedure was repeated, but with substitution of the dipping solutions of Examples 3B and 3C, respectively, for the dipping solution of Example 3A. [0093]
  • An observation of the resulting coatings showed the following: [0094]
  • Tablets Coated with Coating of Ex. 3A: [0095]
  • The coatings were smooth, hard, and shiny, and had no bubbles or cracking. However, the coatings were non-uniform and thin, with land areas not well-covered. Upon exposure to ambient conditions for a six month period, no cracks were seen in the coatings. [0096]
  • Tablets Coated with Coating of Ex. 3B: [0097]
  • The coating were shiny, with few bubbles and no cracking. The coatings were more uniform and rough relative to those of Example 3A. The coatings were also somewhat tacky and thin, with land areas not well-covered. Upon exposure to ambient conditions for a six month period, no cracks were seen in the coatings. [0098]
  • Tablets Coated with Coating of Ex. 3C: [0099]
  • The coatings were shiny with few bubbles and no cracking. The coatings were more uniform and rough relative to those of Example 3A. The coatings were also somewhat tacky and thin, with land areas not well-covered. Upon exposure to ambient conditions for a six month period, no cracks were seen in the coatings. [0100]
  • Example 3H
  • Preparation of Production Scale Dipped Tablets: [0101]
  • Additional subcoated tablets prepared in accordance with Example 2 using the subcoating produced in Example 1H were coated with the resulting dipping solution of Examples 3D using a commercial grade gel-dipping machine in accordance with the procedure described in U.S. Pat. No. 4,820,524, which is incorporated by reference herein. [0102]
  • This procedure was repeated, but with substitution of the dipping solutions of Examples 3E and 3F, respectively, for the dipping solution of Example 3D. [0103]
  • The average percentage weight gain of the dried dipped coatings were as set forth in [0104]
    TABLE F
    Weight Gain of Dried Dip Coating
    % Wt. Gain of Dried
    Example Coating*
    Ex. 3D 0.75-2.26 
    Ex. 3E 1.9-3.52
    Ex. 3F 3.2-5.8 
  • * Relative to weight of dried subcoating and core [0105]
  • This example showed that the addition of xanthan gum to the HPMC dipping solution provided a viscosity enhancement to the dip coating, and thus an increased weight gain of the dip coating on the tablets. [0106]
  • Example 3I
  • Preparation of Dipping Solution of Example 3I [0107]
  • The procedure of Example 3D was repeated, but using the components of Example 3I, as set forth in Table M: [0108]
    TABLE M
    Composition of HPMC Dipping Solutions
    Ingredient Ex 3I* (g) Ex 3J (g)
    HPMC E5 14 12
    Water 85.89 87.88
    HPMC (2910, 0 0
    15 mPs)
    Xanthan gum 0.11 0.12
    PEG 400 0 0
    % (wt.) solids in 14.11 12.12
    dipping solution
  • Example 3J: Preparation of Dipping Solution of Example 3J [0109]
  • The procedure of Example 3D was repeated, but using the components of Example 3J, as set forth in Table M above. [0110]
  • Example 4
  • Preparation of Pre-Gelatinized Starch-Containing Dip Coating Solutions [0111]
  • Dipping solutions comprised of the components set forth in Table G were prepared by dispersing 75 g of the modified waxy maize starch into 200 ml of water under ambient conditions with mixing: [0112]
    TABLE G
    Pre-gelatinized starch-containing Dipping solutions
    Component/Other Example 4A* Example 4B
    Modified waxy maize starch  75 125
    (Purity ® Gum 59)
    water 200 200
    Total weight of solution 275 325
    Wt % solids in dipping solution  27  39
  • [0113]
    TABLE H
    Pre-gelatinized starch-containing Dipping solutions
    With Simethicone of Example 4C
    Amount
    Component Tradename Supplier used*
    Modified waxy maize Purity ® Gum 59 National Starch & 125
    starch Chemical Co.
    Simethicone Antifoam ® 2
    Colloidal silicone Aerosil ® A200 6
    dioxide
    Glycerin 63.5
    Sucrose 38
    colorant Opatint ® 6.9
    water 200
    Total solids 241.4
    TOTAL solution (w/ 441.1
    55% solids)
  • Each side of the subcoated tablets prepared in accordance with Example 2 using the subcoating produced in Example I H were hand-dipped into the dipping solution of Example 4A for a dwell time of about 1 second, pulled up, then dried under ambient conditions. [0114]
  • This procedure was repeated, but with substitution of the dipping solution of Example 4B for the dipping solution of Example 4A and with about a 3 day period between the completion of production of the dipping solution and the commencement of dip coating process. [0115]
  • This procedure was further repeated, but with substitution of the dipping solutions of Example 4C for the dipping solution of Example 4A and with about a 12 hour period between the completion of production of the dipping solution and the commencement of dip coating process. [0116]
  • An observation of the resulting coatings showed the following: [0117]
  • Tablets Coated With Dipping Solution of Ex. 4A: [0118]
  • The coatings were very shiny, hard, smooth, even, and not tacky or cracked. However, the coatings were too thin, and land areas were not covered. No cracking after exposure to ambient conditions for a period of 6 months. [0119]
  • Tablets Coated With Dipping Solution of Ex. 4B: [0120]
  • The coatings were smooth and shiny. Initially the land areas were covered; however, the coatings cracked after exposure to ambient conditions for a period of 6 months. [0121]
  • Tablets Coated With Dipping Solution of Ex. 4C: [0122]
  • The coatings possessed excellent shine and cover, and were smooth with no cracks. No cracking after exposure to ambient conditions for a period of 2 months. [0123]
  • Example 5
  • Preparation of Pre-Gelatinized Starch-Containing Dip Coating Solutions [0124]
  • The procedure set forth in Example 4C is repeated, but without the inclusion of simethicone. Prior to coating the substrate, the solution is exposed to a vacuum pressure of 5 inches Hg in order to remove substantially all of the visible bubbles from the solution. The resulting coating possesses excellent shine and cover, and is smooth with no cracks. [0125]
  • Example 6
  • Effect of Simethicone on Coating Weight Gain [0126]
  • The following dip coating solutions set forth in Table I were prepared to illustrate the effect of simethicone as a weight gain enhancer. Amounts are percent based on the total weight of coating solution. [0127]
    TABLE I
    Dip Coating Solutions
    Ingredient 6A 6B 6C 6D 6E
    HPMC 2910, 12 12 12 12 12
    5 mPs
    Xanthan Gum 1 1 1 1 1
    Simethicone 0 0.035 0.07 0.14 0.25
    Yellow color 6 6 6 6 6
    dispersion***
    Water 81 80.965 80.93 80.86 80.75
  • Dipping solutions A through E, above, were prepared in the following manner: Purified water was heated to about 35° C. HPMC and xanthan gum were added while mixing using a laboratory scale electric mixer (Janke and Kunkel, IKA Labortechnik, Staufen, Germany) with propeller blade at approximately 1000 rpm until the powders appeared uniformly dispersed. Heating was discontinued, and the resulting dispersion was allowed to stand overnight at room temperature. Simethicone and yellow color dispersion were then added with mixing at approximately 500 rpm. [0128]
  • Subcoated cores, prepared according to the method of example 1A, were pre-weighed, then dipped in solutions A, B, C, D, and E, above for a dwell time of about 2 seconds, pulled up, then dried at ambient conditions (about 22° C.). The cores were dipped simultaneously in sets of 7. Three separate sets of seven cores were dipped in each solution A through E. The average weight gain was determined from the triplicate sets of dipped cores from each coating solution. [0129]
  • Resulting weight gains were as follows in Table J: [0130]
    TABLE J
    Average Weight Gain
    Dipping Solution 6A 6B 6C 6D 6E
    Average weight 13.3 20.8 22.3 23.7 19.1
    gain from dip
    coat (mg/tablet)
  • Example 7 Surface Gloss Measurement of Coated Tablets
  • Tablets made according to the preceding examples were tested for surface gloss using an instrument available from TriCor Systems Inc. (Elgin, Ill.) under the tradename, “Tri-Cor Model 805A/806H Surface Analysis System” and generally in accordance with the procedure described in “TriCor Systems WGLOSS 3.4 Model 805A/806H Surface Analysis System Reference Manual” (1996), which is incorporated by reference herein, except as modified below, [0131]
  • This instrument utilized a CCD camera detector, employed a flat diffuse light source, compared tablet samples to a reference standard, and determined average gloss values at a 60 degree incident angle. During its operation, the instrument generated a grey-scale image, wherein the occurrence of brighter pixels indicated the presence of more gloss at that given location. [0132]
  • The instrument also incorporated software that utilized a grouping method to quantify gloss, i.e., pixels with similar brightness were grouped together for averaging purposes. [0133]
  • The “percent full scale” or “percent ideal” setting (also referred to as the “percent sample group” setting), was specified by the user to designate the portion of the brightest pixels above the threshold that will be considered as one group and averaged within that group. “Threshold”, as used herein, is defined as the maximum gloss value that will not be included in the average gloss value calculation. Thus, the background, or the non-glossy areas of a sample were excluded from the average gloss value calculations. The method disclosed in K. Fegley and C. Vesey, “The Effect of Tablet Shape on the Perception of High Gloss Film Coating Systems”, which is available at www.colorcon.com as of 18 March, 2002 and incorporated by reference herein, was used in order to minimize the effects resulting from different tablet shapes, and thus report a metric that was comparable across the industry.(Selected the 50% sample group setting as the setting which best approximated analogous data from tablet surface roughness measurements.). [0134]
  • After initially calibrating the instrument using a calibration reference plate (190-228; 294 degree standard; no mask, rotation 0, depth 0), a standard surface gloss measurement was then created using gel-coated caplets available from McNEIL-PPC, Inc. under the tradename, “Extra Strength Tylenol Gelcaps.” The average gloss value for a sample of 112 of such gel-coated caplets was then determined, while employing the 25 mm full view mask (190-280), and configuring the instrument to the following settings: [0135]
  • Rotation: 0 [0136]
  • Depth: 0.25 inches [0137]
  • Gloss Threshold: 95 [0138]
  • % Full Scale: 50% [0139]
  • Index of Refraction: 1.57 [0140]
  • The average surface gloss value for the reference standard was determined to be 269, using the 50% ideal (50% full scale) setting. [0141]
  • Samples of coated tablets prepared according to the preceding examples were then tested in accordance with the same procedure. The surface gloss values at the 50% ideal setting that were obtained are summarized in Table K below. [0142]
    TABLE K
    Gloss values of coated tablets
    Example No. 3D 3I 3J 4C 6B
    Type of coating dipped dipped dipped poured film dipped
    No. of tablets tested  48  48  51 plate  3
    Gloss Value (% 234 247 229 259 221
    ideal at 50)
  • Additional samples of other, commercially available gel coated tablets were also tested in accordance with the same procedure and compared to the same standard. The results are summarized in Table L below. [0143]
    TABLE L
    Gloss values of commercially available coated tablets
    Excedrin** Excedrin** Extra Extra
    Aspirin Excedrin** Migraine Strength Strength
    Motrin IB* free Migraine Geltab Tylenol Tylenol
    Caplet Caplets Geltab (white Geltabs* Geltabs*
    Product (white) (red) (green side) side) (yellow side) (red side)
    Type of sprayed sprayed gelatin gelatin dipped dipped
    coating film film enrobed enrobed
    No. of tablets  41  40  10  10 112 112
    tested
    Gloss 125 119 270 264 268 268
    Value (%
    ideal at 50)
  • This Example showed that the tablets coated with the compositions of the present invention possessed a high surface gloss value that either was comparable to or exceeded that possessed by commercially-available gelatin coated tablets. In contrast, typical sprayed films possessed a substantially lower surface gloss, e.g. 119 to 125 in this Example. [0144]
  • Example 8
  • Preparation of Coated tablets [0145]
  • Example 8A
  • Preparation of Tablets Spray Coated With Opadry® II Subcoating [0146]
  • 122.8 kg (18% w/w) of a prepared blend containing HPMC 2910-6cP, maltodextrin, HPMC2910-3cP, HPMC2910-50cP, and PEG-400 (commercially available from Colorcon Inc., West Point, PA as “Opadry® II”) was added with mixing into 559.7 kg (82% w/w) of 35° C. purified water in a conventional pressure pot, and mixed with an air-driven propeller-type Lightnin mixer at a speed of 500 rpm. After the powder was completely added, the dispersion was mixed at 500 rpm for 2 hours, then allowed to stand without mixing at ambient conditions for 12 hours. [0147]
  • The resulting film coating dispersion was then applied onto compressed acetaminophen tablets, which were prepared in accordance with the procedure set forth in Example 1 of U.S. Pat. No. 5,658,589 (“'589 patent”), which is incorporated by reference herein, via spraying in accordance with the procedure set forth in the examples of the '589 patent. The resulting spray-coated tablets possessed a 4% weight gain relative to the weight of the uncoated tablet cores. [0148]
  • Examples 8B Preparation of Tablets Spray Coated with HPMC/Castor Oil Subcoating
  • 88.4 kg (9% w/w) of hydroxypropyl methylcellulose 2910, 5 mPs and 0.347 kg (0.04% w/w) of castor Oil were mixed into 593.8 kg (91% w/w) of purified water at 35° C. in a tank with mixer (Lee Industries) at a speed of 1750 rpm. After the powder was completely added, the mixer speed was increased to 3500 rpm for 15 minutes. The mixer speed was then reduced to 1750 rpm while the pressure was reduced to 15 inches of water for 2 hours to deaerate the dispersion. [0149]
  • The resulting film coating dispersion was then applied onto the compressed acetaminophen tablets of Example 8A via spraying in accordance with the procedure set forth above in Example 8A. The resulting spray coated tablets possessed a 4% weight gain relative to the weight of the uncoated tablet cores. [0150]
  • Example 8C Preparation of Tablets Dip Coated with HPMC/Castor Oil Dipping Solutions
  • A dipping solution comprised of the components set forth in Table M below was produced: [0151]
    TABLE M
    HPMC/Castor Oil Clear Dipping Solutions
    Example A&B C&D E&F
    HPMC 2910    9%   13%   13%
    5 mPs
    Castor Oil  0.04%  0.05%  0.05%
    Purified Water 90.96% 86.95% 86.95%
  • Purified water was heated to 80° C., then added to a Lee jacketed mix tank while mixing at a speed of 1750 rpm. After HPMC 2910, 5 mPs and castor oil were added thereto with mixing, the mixer speed was increased to 3500 rpm for 15 minutes. The mixer speed was then reduced to 1750 rpm while the temperature of the dispersion was reduced to 35° C. and the pressure was reduced to 15 inches water for deaeration. After mixing the dispersion for 2 hours, the resulting dispersion remained under constant pressure conditions for an additional 3 hours without mixing. [0152]
  • The colorant of Example 8C-a was then added to 96 kg of the resulting clear dipping solutions with mixing at a 1750 rpm speed in the amounts set forth in Table N below: [0153]
    TABLE N
    HPMC/Castor Oil Colored Dipping Solutions
    Example 8C-a 8C-b 8C-c 8C-d 8C-e 8C-f
    Colorant Opatint Opatint Opatint Opatint Opatint Opatint
    (DD-1761) (DD-2125) (DD-1761) (DD-2125) (DD-10516) (DD-18000)
    Amount of 2.700 2.570 2.700 2.570 4.072 2.175
    colorant
    (kg)
    Color red yellow red yellow blue white
    Visc/Temp 490 cps @ 518 cps @ 612 cps @ 457 cps @ 351 cps @ 319 cps @
    40 C. 40 C. 30 C. 30 C. 40 C. 40 C.
    Dipping 40 C. 40 C. 30 C. 30 C. 40 C. 40 C.
    Temp
    Weight Gain 16* 16* 26** 26** 20*** 20***
    in dipping
    (mg/tablet)
    Gloss 229 229 249 228 238 233
  • This procedure was independently repeated for each of the colorants set forth above in Table N. [0154]
  • Subcoated tablets, which were prepared in accordance with the procedure set forth above in Example 8A, were dip-coated with the dip-coating solution prepared in accordance with Example 8C-a and 8C-b using a commercial grade gel-dipping machine and in accordance with the procedure described in U.S. Pat. No. 4,820,524, which is incorporated by reference herein, using the dipping solution temperatures reported in the table above. This procedure was independently repeated on subcoated tablets, which were prepared in accordance with the procedure set forth above in Example 8B, for each of the colored dipping solutions 8C-c through 8C-f in Table N above. [0155]
  • A visual comparison of the dip-coated tablets prepared according to examples 8C-a and 8C-b with those prepared in accordance with Examples 8C-c through 8C-f revealed that the former did not possess complete coating coverage around the edges of the tablets. By contrast, the dip-coated tablets prepared according to examples 8C-c through 8C-f possessed a superior good coating coverage around the tablet edges. This indicated that a weight gain of 16 mg per gelcap (such as that produced by the 9% HPMC formula of examples 8C-a and 8C-b) was insufficient for the HPMC/Castor Oil dipping formula, while a weight gain of 20 to 26 mg per gelcap/geltab (such as that produced by the 13% HPMC formula of examples 8C-c through 8C-f) provided good coverage. [0156]
  • In addition, a visual comparison of the HPMC/Castor Oil dip-coated tablets of Examples 8C-c through 8C-f and the HPMC/Xanthan Gum dip-coated tablets of Examples 3I and 3J indicated that the former possessed superior gloss and surface smoothness. The superior gloss and smoothness were likely attributed to the inclusion of castor oil in the dip coating. [0157]
  • Example 9
  • Preparation of Tablets Dip Coated with HPMC/Maltodextrin/PEG Dipping Solutions [0158]
  • 143.3 kg (21% w/w) of the Opadry® II blend of Example 8A was added into 539.2 kg (79% w/w) of 35° C. purified water while mixing at a speed of 3500 rpm for 15 minutes. The mixer speed was then decreased to 1750 rpm, and the tank evacuated to 30 PSIA to deaerate the solution for 5 hours. 2.70 kg of Colorant (Opatint® Red DD-1761, from Colorcon Inc.) was then added to 96 kg of the clear dipping solution while mixing at a speed of 1750 rpm. 2.570 kg of Colorant (Opatint® Yellow DD-2125, from Colorcon Inc.) was then added to a second 96 kg portion of the clear dipping solution while mixing at a speed of 1750 rpm until dispersed. [0159]
  • Subcoated tablets, which were prepared in accordance with the procedure and materials set forth above in Example 8B, were dip-coated with the dip-coating solution prepared in accordance with this Example using a commercial grade gel-dipping machine and in accordance with the procedure described in U.S. Pat. No. 4,820,524, which is incorporated by reference herein, using a dipping solution temperature of 30° C. The viscosity of the dipping solutions was 607 cPs at 30° C. for the yellow solution, and 677 cPs at 30° C. for the red solution. An average weight gain of about 27 mg/gelcap was obtained. [0160]
  • Seventy-two (72) dipped gel caps produced in accordance with this Example were tested for surface gloss in accordance with the procedure set forth in Example 7. The average surface gloss for these dipped gelcaps was 258 gloss units. [0161]
  • Example 10
  • Preparation of Tablets Dip Coated with HPMC/Carrageenan Dipping Solutions [0162]
  • 88.4 kg (13% w/w) of HPMC 2910-5 mPs, 0.347 kg of Castor Oil (0.05% w/w), and 0.68 kg (0.1% w/w) of kappa Carrageenan-911 were added into a tank containing 590 kg (87% w/w) of 80° C. purified water while mixing at a speed of 1750 rpm. After the addition was complete, the mixer speed was increased to 3500 rpm for 15 minutes. The mixer speed was then decreased to 1750 rpm, and the tank evacuated to 15 inches of water to deaerate the solution for 2 hours. Mixing was then stopped, and the dispersion was allowed to stand at constant pressure for an additional 3 hours. 2.175 kg of Colorant (Opatint® White DD-18000, from Colorcon Inc.) was then added to 96 kg of the clear dipping solution while mixing at a speed of 1750 rpm. 4.072 kg of Colorant (Opatint® Blue DD-10516, from Colorcon Inc.) was then added to a second 96 kg portion of the clear dipping solution while mixing at a speed of 1750 rpm until dispersed. [0163]
  • Subcoated tablets, which were prepared in accordance with the procedure and materials set forth above in Example 8B, were dip-coated with the dip-coating solution prepared in accordance with this Example using a commercial grade gel-dipping machine and in accordance with the procedure described in U.S. Pat. No. 4,820,524, which is incorporated by reference herein, using a dipping solution temperature of 40° C. An average weight gain of about 20 mg/gelcap was obtained. [0164]
  • Eighty-eight (88) dipped gel caps produced in accordance with this Example were tested for surface gloss in accordance with the procedure set forth in Example 7. The average surface gloss for these dipped geltabs was 232 gloss units. [0165]

Claims (40)

    We claim:
  1. 1. A water soluble composition for dip-coating a substrate comprised of:
    a) hydroxypropylmethyl cellulose; and
    b) a thickener selected from the group consisting of xanthan gum, carrageenan, and mixtures thereof, wherein the composition possesses a surface gloss of at least 150 when applied via dip coating to a substrate.
  2. 2. The composition of claim 1, wherein the composition is comprised of, based upon the total dry weight of the composition,
    a) from about 95 percent to less than about 100 percent of hydroxypropylmethyl cellulose; and
    b) from about 0.5 percent to about 5 percent of a thickener selected from the group consisting of xanthan gum, carrageenan, and mixtures thereof,.
  3. 3. The composition of claim 1, wherein the composition is comprised of, based upon the total dry weight of the composition,
    a) from about 95 percent to about 99.5 percent of hydroxypropylmethyl cellulose; and
    b) from about 0.5 percent to about 5 percent of xanthan gum.
  4. 4. The composition of claim 2 further comprising, based upon the total dry weight of the composition, up to about 40% plasticizers.
  5. 5. The composition of claim 4 wherein the plasticizers are selected from the group consisting of polyethylene glycol, glycerin, sorbitol, triethyl citrate, tribuyl citrate, dibutyl sebecate, vegetable oils, surfactants, propylene glycol, mono acetate of glycerol, diacetate of glycerol, triacetate of glycerol, natural gums, and mixtures thereof.
  6. 6. The composition of claim 4, wherein the plasticizers are selected from the group consisting of glycerin, polyethylene glycol, propylene glycol, castor oil, and mixtures thereof.
  7. 7. The composition of claim 2 further comprising, based upon the total dry weight of the composition, up to about 14% of a coloring agent.
  8. 8. The composition of claim 7 wherein the coloring agent is selected from the group consisting of azo dyes, quinopthalone dyes, triphenylmethane dyes, xanthene dyes, indigoid dyes, iron oxides, iron hydroxides, titanium dioxide, natural dyes, and mixtures thereof.
  9. 9. A dosage form for delivering an active agent, the form comprising an outer coating, said outer coating comprising the composition of claim 2.
  10. 10. A pharmaceutical dosage form comprising an outer coating of the composition of claim 2.
  11. 11. A pharmaceutical dosage form comprising a core, a subcoating substantially covering said core, and an outer coating substantially covering said subcoating, wherein the outer coating is comprised of the composition of claim 2.
  12. 12. The coated dosage form of claim 11 wherein the subcoating comprises materials selected from the group consisting of cellulose ethers, plasticizers, polycarbohydrates, pigments, opacifiers, and mixtures thereof.
  13. 13. The coated dosage form of claim 11 wherein the subcoating comprises materials selected from the group consisting of hydroxypropylmethylcellulose, castor oil, polyethylene glycol, polysorbate 80, maltodextrin, and mixtures thereof.
  14. 14. The dosage form of claim 11 wherein the subcoating is comprised of, based upon the total dry weight of the subcoating,
    a) from about 2 percent to about 8 percent of a water-soluble cellulose ether selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, and mixtures thereof.
    b) from about 0.1 percent to about 1 percent castor oil.
  15. 15. The dosage form of claim 11 wherein the subcoating is comprised of, based upon the total dry weight of the subcoating,
    a) from about 4 percent to about 6 percent hydroxypropylmethylcellulose; and
    b) from about 0.1 percent to about 1 percent castor oil.
  16. 16. The dosage form of claim 15 wherein the hydroxypropylmethylcellulose has a viscosity of about 5000 cps in an aqueous solution containing 2 weight percent hydroxypropylmethylcellulose.
  17. 17. The dosage form of claim 11 wherein the subcoating is comprised of, based upon the total dry weight of the subcoating,
    a) from about 20 percent to about 50 percent hydroxypropylmethylcellulose;
    b) from about 45 percent to about 75 percent maltodextrin;
    c) from about 1 percent to about 10 percent PEG 400.
  18. 18. The coated dosage form of claim 11, wherein the coating is comprised of, based upon the total dry weight of the subcoating,
    a) from about 25 percent to about 40 percent hydroxyethylcellulose;
    b) from about 50 percent to about 70 percent maltodextrin;
    c) from about 5 percent to about 10 percent PEG 400.
  19. 19. A tablet coated with the film forming composition according to claim 2.
  20. 20. The coated dosage form of claim 11, further comprising an effective amount of a pharmaceutical active ingredient, wherein said dosage form meets USP dissolution requirements for immediate release forms of said pharmaceutical active ingredient.
  21. 21. An aqueous dispersion of the composition of claim 2 for the manufacture of dip-coated tablets.
  22. 22. The aqueous dispersion of claim 21 comprised of, based upon the total weight of the aqueous dispersion,
    a) from about 10 percent to about 14 percent of hydroxypropylmethylcellulose; and
    b) from about 0.1 percent to about 0.14 percent of xanthan gum.
  23. 23. The composition of claim 1 which is substantially free of gelatin.
  24. 24. Use of the aqueous dispersion of claim 21 for the manufacture of dip coated tablets.
  25. 25. A pharmaceutical dosage form comprising a core and a coating, said coating substantially covering said core and having a surface gloss of at least 150; wherein said coating comprises the composition of claim 1.
  26. 26. The composition of claim 2 further comprising a weight enhancer selected from the group consisting of simethicone, polysorbate 80, and mixtures thereof.
  27. 27. A simulated capsule-like medicament comprising:
    a. a core having a first end and a second end,
    b. a first coating layer having a first color provided on said first end of said core;
    c. a second coating layer having a second color on said second end of said core, said first color is different from said second color; wherein at least one of said first coating layer and second coating layer comprises the composition of claim 1.
  28. 28. The medicament of claim 27 wherein at least one of said first coating layer and said second coating layer is comprised of a coating composition, said coating composition comprised of, based upon the total dry weight of the coating composition,
    a) from about 95 percent to less than about 100 percent of hydroxypropylmethyl cellulose; and
    b) from about 0.5 percent to about 5 percent of xanthan gum.
  29. 29. The medicament of claim 28 further comprising a subcoating layer substantially covering said core, said subcoating layer provided between said core and said first coating layer and said second coating layer.
  30. 30. The medicament of claim 29 wherein the subcoating comprises materials selected from the group consisting of cellulose ethers, plasticizers, polycarbohydrates, pigments, opacifiers, and mixtures thereof.
  31. 31. A water soluble composition for dip-coating a substrate comprised of:
    a) hydroxypropylmethyl cellulose; and
    b) castor oil,
    wherein the composition possesses a surface gloss of at least 150 when applied via dip coating to a substrate.
  32. 32. A pharmaceutical dosage form comprising a core and a coating, said coating substantially covering said core; wherein said coating comprises the composition of claim 31.
  33. 33. Use of the composition of claim 31 for the manufacture of dip coated tablets.
  34. 34. A water soluble composition for dip-coating a substrate comprised of:
    a) hydroxypropylmethyl cellulose; and
    b) maltodextrin,
    wherein the composition possesses a surface gloss of at least 150 when applied via dip coating to a substrate.
  35. 35. The composition of claim 34 further comprising polyethylene glycol.
  36. 36. A pharmaceutical dosage form comprising a core and a coating, said coating substantially covering said core; wherein said coating comprises the composition of claim 34.
  37. 37. Use of the composition of claim 34 for the manufacture of dip coated tablets.
  38. 38. The water soluble composition of claim 1, wherein the composition is comprised of, based upon the total dry weight of the composition:
    a) greater than about 95 percent and less than about 99.5 percent of hydroxypropylmethyl cellulose; and
    b) greater than about 0.5 percent and less than about 5 percent of carrageenan,
    wherein the composition possesses a surface gloss of at least 150 when applied via dip coating to a substrate.
  39. 39. A pharmaceutical dosage form comprising a core and a coating,
    said coating substantially covering said core; wherein said coating comprises the composition of claim 38.
  40. 40. Use of the composition of claim 38 for the manufacture of dip coated tablets.
US10122999 2001-05-15 2002-04-12 Dip coating compositions containing cellulose ethers Abandoned US20030070584A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US29112701 true 2001-05-15 2001-05-15
US32572601 true 2001-09-28 2001-09-28
US10122999 US20030070584A1 (en) 2001-05-15 2002-04-12 Dip coating compositions containing cellulose ethers

Applications Claiming Priority (37)

Application Number Priority Date Filing Date Title
US10122999 US20030070584A1 (en) 2001-05-15 2002-04-12 Dip coating compositions containing cellulose ethers
US10122498 US20030072729A1 (en) 2001-05-15 2002-04-15 Simethicone as weight gain enhancer
AU4061702A AU4061702A (en) 2001-05-15 2002-05-13 Dip coating compositions containing starch or dextrin
AU4061802A AU4061802A (en) 2001-05-15 2002-05-13 Dip coating compostions containing cellulose ethers
MXPA02004823A MXPA02004823A (en) 2001-05-15 2002-05-14 Dip coating compositions containing cellulose ethers.
MXPA02004824A MXPA02004824A (en) 2001-05-15 2002-05-14 Dip coating compositions containing starch or dextrin.
AR034335A1 AR034335A1 (en) 2001-05-15 2002-05-14 Coating compositions containing immersion cellulose ethers
CA 2386339 CA2386339C (en) 2001-05-15 2002-05-14 Dip coating compositions containing cellulose ethers
JP2002139169A JP2003012561A (en) 2001-05-15 2002-05-14 Dip-coating composition including cellulose ether
NZ51895002A NZ518950A (en) 2001-05-15 2002-05-14 Dip coating compositions containing cellulose ethers with a gloss value of at least 150 and the coating is devoid of gelatine
EP20020253341 EP1260218B1 (en) 2001-05-15 2002-05-14 Dip coating compositions containing starch or dextrin
JP2002139176A JP2003089659A (en) 2001-05-15 2002-05-14 Dip coating composition containing starch or dextrin
AR036998A1 AR036998A1 (en) 2001-05-15 2002-05-14 film-forming compositions, pharmaceutical dosage forms and medicine as imitation capsule comprising them, a method to improve color uniformity of a layer of coating composition and method for increasing the weight gain of a layer of
AR035899A1 AR035899A1 (en) 2001-05-15 2002-05-14 film-forming compositions, pharmaceutical dosage forms, simulated capsule type drugs and method for preparing coated tablets
KR20020026456A KR20020087370A (en) 2001-05-15 2002-05-14 Dip coating compositions containing cellulose ethers
ES02253342T ES2323526T3 (en) 2001-05-15 2002-05-14 Compositions for dip coating comprising cellulose esters.
CA 2386430 CA2386430A1 (en) 2001-05-15 2002-05-14 Simethicone as weight gain enhancer
CA 2386278 CA2386278C (en) 2001-05-15 2002-05-14 Dip coating compositions containing starch or dextrin
DE2002631850 DE60231850D1 (en) 2001-05-15 2002-05-14 Compositions for dip coating containing cellulose ethers
KR20020026391A KR20020087367A (en) 2001-05-15 2002-05-14 Dip coating compositions containing starch or dextrin
EP20020253340 EP1260217A3 (en) 2001-05-15 2002-05-14 Simethicone as weight gain enhancer for coating compositions
JP2002139178A JP2003012560A (en) 2001-05-15 2002-05-14 Film-forming composition using simethicone as extension improving agent
AT02253341T AT516798T (en) 2001-05-15 2002-05-14 Dip-coating compositions containing starch or dextrin
EP20020253342 EP1260219B1 (en) 2001-05-15 2002-05-14 Dip coating compositions containing cellulose ethers
AT02253342T AT427741T (en) 2001-05-15 2002-05-14 Compositions for dip coating containing cellulose ethers
NZ51895102A NZ518951A (en) 2001-05-15 2002-05-14 Dip coating compositions containing starch or dextrin with a surface gloss value of at least 150 and contains less than 1% gelatine
BR0201905A BR0201905A (en) 2001-05-15 2002-05-15 Compositions for immersion coating containing starch or dextrine
CN 02121867 CN1429545A (en) 2001-05-15 2002-05-15 Dimethyl silicone oil used as weighting reinforcing agent
CN 02121869 CN1388189A (en) 2001-05-15 2002-05-15 Dip-coating composition containing cellulose ether
CN 02121868 CN1388190A (en) 2001-05-15 2002-05-15 Dis-coating composition containing starch or starch gum
BR0201904A BR0201904A (en) 2001-05-15 2002-05-15 Dip Coating compositions containing cellulose ethers
BR0202523A BR0202523A (en) 2001-09-28 2002-05-15 Simethicone as weight gain enhancer
CO02041350A CO5390071A1 (en) 2001-05-15 2002-05-15 Coating compositions containing starch or immersion extrina
CO02041349A CO5400143A1 (en) 2001-05-15 2002-05-15 Coating compositions containing immersion cellulose ethers
KR20020026834A KR20020087380A (en) 2001-05-15 2002-05-15 Simethicone as weight gain enhancer
US11769028 US7785650B2 (en) 2001-05-15 2007-06-27 Method for dip coating dosage forms
US12335069 US20090092739A1 (en) 2001-05-15 2008-12-15 Method of dip-coating dosage forms

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10122531 Continuation-In-Part US20030072731A1 (en) 2001-05-15 2002-04-15 Dip coating compositions containing starch or dextrin
US10122498 Continuation-In-Part US20030072729A1 (en) 2001-05-15 2002-04-15 Simethicone as weight gain enhancer
US11769028 Continuation US7785650B2 (en) 2001-05-15 2007-06-27 Method for dip coating dosage forms

Publications (1)

Publication Number Publication Date
US20030070584A1 true true US20030070584A1 (en) 2003-04-17

Family

ID=27382893

Family Applications (2)

Application Number Title Priority Date Filing Date
US10122999 Abandoned US20030070584A1 (en) 2001-05-15 2002-04-12 Dip coating compositions containing cellulose ethers
US11769028 Active US7785650B2 (en) 2001-05-15 2007-06-27 Method for dip coating dosage forms

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11769028 Active US7785650B2 (en) 2001-05-15 2007-06-27 Method for dip coating dosage forms

Country Status (8)

Country Link
US (2) US20030070584A1 (en)
EP (1) EP1260219B1 (en)
JP (1) JP2003012561A (en)
KR (1) KR20020087370A (en)
CN (1) CN1388189A (en)
CA (1) CA2386339C (en)
DE (1) DE60231850D1 (en)
ES (1) ES2323526T3 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
US20040253312A1 (en) * 2001-09-28 2004-12-16 Sowden Harry S. Immediate release dosage form comprising shell having openings therein
US20050152970A1 (en) * 2004-01-13 2005-07-14 Rinker Roger A. Rapidly disintegrating gelatinous coated tablets
US20050152971A1 (en) * 2004-01-13 2005-07-14 Rinker Roger A. Rapidly disintegrating gelatinous coated tablets
US20070104755A1 (en) * 2005-11-08 2007-05-10 Sterling Bernhard B Method and system for treatment of eating disorders
US20070104754A1 (en) * 2005-11-08 2007-05-10 Sterling Bernhard B Method and system for treatment of eating disorders
US20070213411A1 (en) * 2003-11-05 2007-09-13 The Australian National University Dispersions And Methods Of Preparing Them
US20090074866A1 (en) * 2007-09-17 2009-03-19 Jen-Chi Chen Dip coated compositions containing copolymer of polyvinyl alcohol and polyethylene glycol and a gum
US20090191267A1 (en) * 2005-09-30 2009-07-30 Wynn David W Oral Compositions Containing a Salivation Inducing Agent
US20090208574A1 (en) * 2008-02-19 2009-08-20 Jen-Chi Chen Dip coated compositions containing a starch having a high amylose content
US20110135694A1 (en) * 2009-12-07 2011-06-09 Saumitra Bagchi Partial dip coating of dosage forms for modified release
US8420057B2 (en) 2011-09-01 2013-04-16 Qualicaps, Inc. Capsule having broad color spectrum
US8435545B2 (en) 2011-09-01 2013-05-07 Qualicaps, Inc. Capsule having broad color spectrum

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429724B1 (en) * 2001-09-28 2013-11-06 McNeil-PPC, Inc. Dosage form containing a confectionery composition
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
CN101084016A (en) * 2004-04-15 2007-12-05 克艾思马有限公司 Compositions capable of facilitating penetration across a biological barrier
WO2005120466A3 (en) * 2004-06-07 2007-04-19 Wyeth Corp Sugar coatings and methods therefor
US20060093560A1 (en) * 2004-10-29 2006-05-04 Jen-Chi Chen Immediate release film coating
GB0703319D0 (en) * 2007-02-21 2007-03-28 Dredge Dean W Method and composition for surface coating
CA2700480A1 (en) * 2007-09-28 2009-04-02 Lintec Corporation Orally-administered agent
RU2552324C2 (en) 2008-09-17 2015-06-10 Киазма Инк. Pharmaceutical compositions and respective delivery methods
US9603805B2 (en) 2011-09-30 2017-03-28 Mochida Pharmaceutical Co., Ltd. Easily dosable solid preparation
JP5908295B2 (en) * 2012-02-03 2016-04-26 カバヤ食品株式会社 New soft confectionery and a method of manufacturing the same, including the menthol
JP2013169146A (en) * 2012-02-17 2013-09-02 Kabaya Shokuhin Kk New refreshing confectionery and method for producing the same
US20180008562A1 (en) * 2016-07-05 2018-01-11 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Oral Dosage Form Containing a Fast Release Exterior Coating

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411746A (en) * 1993-02-24 1995-05-02 Warner-Jenkinson Company, Inc. Dye compositions and methods for film coating tablets and the like
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5560926A (en) * 1993-02-10 1996-10-01 Merck Patent Gesellschaft Mit Beschrankter Haftung Process for the production of an S-ibuprofen-containing tablet
US5681684A (en) * 1995-09-20 1997-10-28 National Starch And Chemical Investment Holding Corporation Photosensitive resin composition
US5698220A (en) * 1988-08-30 1997-12-16 Pfizer Inc. Asymmetric membranes in delivery devices
US6113945A (en) * 1996-02-26 2000-09-05 L. Perrigo Company Multi-colored medicament

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1787777A (en) 1926-12-10 1931-01-06 Parke Davis & Co Capsule machine
US3185626A (en) 1963-03-06 1965-05-25 Sterling Drug Inc Tablet coating method
US3652294A (en) 1970-08-19 1972-03-28 Nat Starch Chem Corp Manufacture of starch-containing food products
US3751277A (en) 1971-03-24 1973-08-07 Dow Chemical Co Tablet coating process and composition
US3802896A (en) 1972-05-15 1974-04-09 Nutrilite Products Color concentrated base dispersion used in tablet film coating
US4001211A (en) 1974-12-02 1977-01-04 The Dow Chemical Company Pharmaceutical capsules from improved thermogelling methyl cellulose ethers
GB1543167A (en) 1976-01-08 1979-03-28 Tate & Lyle Ltd Sweeteners
US4683256A (en) 1980-11-06 1987-07-28 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4267164A (en) 1980-01-31 1981-05-12 Block Drug Company Inc. Effervescent stannous fluoride tablet
US4313765A (en) 1980-09-24 1982-02-02 Merck & Co., Inc. Synergistic blends of cellulase-free xanthan gum and cellulosics
EP0056825B1 (en) 1981-01-22 1984-12-05 Capsugel A.G. A process for producing a pharmaceutical capsule having enteric properties
DK151608C (en) 1982-08-13 1988-06-20 Benzon As Alfred A process for preparing a pharmaceutical oral controlled release multiple-
JPS59193831A (en) 1983-04-18 1984-11-02 Sankyo Co Ltd Preparation of enteric drug
US4505890A (en) 1983-06-30 1985-03-19 E. R. Squibb & Sons, Inc. Controlled release formulation and method
US4576646A (en) 1983-07-06 1986-03-18 Seppic Film-forming compositions for enveloping solid forms, particularly pharmaceutical or food products or seeds, and products obtained, coated with said compositions
JPS6124516A (en) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd Long active tablet
US4643894A (en) 1984-07-24 1987-02-17 Colorcon, Inc. Maltodextrin coating
US4828841A (en) 1984-07-24 1989-05-09 Colorcon, Inc. Maltodextrin coating
JPH0456007B2 (en) 1984-10-23 1992-09-07 Shinetsu Chem Ind Co
US4652313A (en) 1984-10-24 1987-03-24 Crompton And Knowles Corporation Aqueous lake pigment suspension
GB8507779D0 (en) 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
US4601894A (en) 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4695591A (en) 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4904476A (en) 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US4853249A (en) 1985-11-15 1989-08-01 Taisho Pharmaceutical Co., Ltd. Method of preparing sustained-release pharmaceutical/preparation
US4892742A (en) 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
US5023108A (en) 1986-01-13 1991-06-11 Research Corporation Aqueous dispersions of waxes and lipids for pharmaceutical coating
GB8601204D0 (en) 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
GB8610573D0 (en) 1986-04-30 1986-06-04 Haessle Ab Pharmaceutical formulations of acid labile substances
US4802924A (en) 1986-06-19 1989-02-07 Colorcon, Inc. Coatings based on polydextrose for aqueous film coating of pharmaceutical food and confectionary products
US4820529A (en) 1986-06-26 1989-04-11 Asahi Denka Kogyo Kabushiki Kaisha Process for preparing pasty proteinous material or proteinous food from crustaceans
JPH0570494B2 (en) 1986-09-03 1993-10-05 Matsutani Kagaku Kogyo Kk
GB8628359D0 (en) 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4981698A (en) 1986-12-23 1991-01-01 Warner-Lambert Co. Multiple encapsulated sweetener delivery system and method of preparation
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4816259A (en) 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
US4820524A (en) 1987-02-20 1989-04-11 Mcneilab, Inc. Gelatin coated caplets and process for making same
US4913893A (en) 1987-08-28 1990-04-03 Clairol Incorporated Aerosol hair setting composition containing an alginate
JPH07100665B2 (en) 1987-12-23 1995-11-01 信越化学工業株式会社 The method of manufacturing coated medicament
US5164195A (en) 1988-04-19 1992-11-17 Southwest Research Institute Method of oral delivery with an adherent controlled-release salt sensitive capsule
US5064650A (en) 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US4880636A (en) 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US5009897A (en) 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
US4999189A (en) 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
US5186930A (en) 1988-11-14 1993-02-16 Schering Corporation Sustained release oral suspensions
US4965089A (en) 1989-04-10 1990-10-23 Sauter Manufacturing Corp. Method and apparatus for the gelatin coating of caplets
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5059416A (en) 1989-06-26 1991-10-22 Warner-Lambert Company Zinc compound delivery system with improved taste and texture
US5082669A (en) 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
US5146730A (en) 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US5248516A (en) 1989-12-19 1993-09-28 Fmc Corporation Film-forming composition: method of producing same and use for coating pharmaceuticals and foods and the like
US5209933A (en) 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
US5198227A (en) 1990-01-22 1993-03-30 Mcneil-Ppc, Inc. Dual subcoated simulated capsule medicament
US5077053A (en) 1990-02-12 1991-12-31 Warner-Lambert Company Zein as a moisture barrier for sugarless edible compositions and method for preparing same
FR2660317B1 (en) 1990-03-27 1994-01-14 Seppic Film-forming product indicated to the coating of solid forms; process for its manufacture and products covered products of this product.
JP3165438B2 (en) * 1990-04-04 2001-05-14 バーウィンド・ファーマス―ティカル・サーヴィスィーズ・インコーポレーテッド Maltodextrin and cellulosic polymer film coating in an aqueous
US5213738A (en) 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5136031A (en) 1990-07-09 1992-08-04 Tate & Lyle Public Limited Company Chlorination of sugars
CA2042529C (en) 1990-08-10 2002-07-30 Chokyun Rha Polysaccharide article and uses therefor
US5228909A (en) 1990-10-22 1993-07-20 Aqualon Company Sodium formate fluidized polymer suspensions
US5228916A (en) 1990-11-05 1993-07-20 Mcneil-Ppc, Inc. Apparatus for creating a gelatin coating
US5436026A (en) 1990-11-05 1995-07-25 Mcneil-Ppc, Inc. Discharge and transfer system for apparatus for gelatin coating tablets
US5538125A (en) 1990-11-05 1996-07-23 Mcneil-Ppc, Inc. Indexing and feeding systems for apparatus for gelatin coating tablets
US5503673A (en) 1990-11-05 1996-04-02 Mcneil-Ppc, Inc Apparatus for dip coating product
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5098715A (en) 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
US5591455A (en) * 1990-12-20 1997-01-07 Warner-Jenkinson Company, Inc. Wet powder film-forming compositions
GB9104890D0 (en) 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
WO1993014158A1 (en) 1992-01-17 1993-07-22 Berwind Pharmaceutical Services, Inc. Film coatings and film coating compositions based on cellulosic polymers and lactose
US5571533A (en) 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
JP3279325B2 (en) 1991-06-14 2002-04-30 チノン株式会社 Autofocus system
DE69229881T2 (en) 1991-10-04 1999-12-09 Yoshitomi Pharmaceutical A sustained release tablet
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
EP0546593B1 (en) 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5286502A (en) 1992-04-21 1994-02-15 Wm. Wrigley Jr. Company Use of edible film to prolong chewing gum shelf life
US5270071A (en) 1992-06-18 1993-12-14 Mcneil-Ppc, Inc. Reduced calorie fruit spreads
US5843479A (en) 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5382435A (en) 1993-03-24 1995-01-17 Southwest Research Institute Microparticulate pharmaceutical delivery system
US5635208A (en) 1993-07-20 1997-06-03 Mcneil-Ppc, Inc. Granulation process for producing an acetaminophen and diphenhydramine hydrochloride composition and composition produced by same
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
CA2129079C (en) 1993-08-03 2006-01-17 Tatsuo Nomura Orally administrable cholesterol lowering agent
JP2916978B2 (en) 1993-08-25 1999-07-05 エスエス製薬株式会社 Release start control formulations
CA2164344C (en) 1993-08-30 2004-06-29 Stanley Lech Tablet coating based on a melt-spun mixture of a saccharide and a polymer
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
JPH09510182A (en) 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド Clear liquid for drug delivery that are encapsulated
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
DE670160T1 (en) 1994-03-01 1996-03-14 Gerhard Gergely An effervescent system and an active drug-containing granular product or tablet, as well as processes for their preparation.
JP2917799B2 (en) 1994-03-11 1999-07-12 田辺製薬株式会社 Gastrointestinal place release formulation
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5482718A (en) 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
GB9408448D0 (en) 1994-04-28 1994-06-22 Procter & Gamble Granular detergent composition
FR2719999B1 (en) 1994-05-17 1996-08-02 Georges Serge Grimberg gum base pharmaceutical composition of guar and a neutralizing antacid, which can be added a variety of therapeutic active ingredients.
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
JP3355593B2 (en) 1994-08-19 2002-12-09 信越化学工業株式会社 Method of manufacturing a solid enteric agent
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5498709A (en) 1994-10-17 1996-03-12 Mcneil-Ppc, Inc. Production of sucralose without intermediate isolation of crystalline sucralose-6-ester
US6083430A (en) 1994-10-28 2000-07-04 Fuisz Technologies Ltd. Method of preparing a dosage unit by direct tableting and product therefrom
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5756123A (en) * 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
JP2959423B2 (en) * 1994-12-01 1999-10-06 シオノギクオリカプス株式会社 Encapsulating coating composition
US6245350B1 (en) 1994-12-16 2001-06-12 Warner-Lambert Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
JP3670016B2 (en) 1994-12-16 2005-07-13 ワーナー−ランバート・カンパニー Solid dosage forms may be obtained by the methods and according method for encapsulating caplets in a capsule
CN1132070A (en) 1994-12-21 1996-10-02 麦克尼尔-Ppc公司 Aqueous suspension formulation for pharmaceutical applications
EP0807433A4 (en) 1994-12-27 2005-12-28 Akzo Nobel Nv Sustained-release preparation
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
JP3507211B2 (en) 1995-07-13 2004-03-15 三菱化学株式会社 Sugar-coating liquid and the sugar-coated tablets
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
JP3225340B2 (en) 1995-07-27 2001-11-05 株式会社新川 Attracting and holding unit of the lead frame
DE19539361A1 (en) 1995-10-23 1997-04-24 Basf Ag A process for producing multilayer, solid drug forms for oral or rectal administration
US6123964A (en) 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
US5712310A (en) 1996-06-14 1998-01-27 Alpharma Uspd, Inc. Suspension of substantially water-insoluble drugs and methods of their manufacture
US5830503A (en) 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
GB9615283D0 (en) 1996-07-20 1996-09-04 Cerestar Holding Bv A method for precoating of chewing gum and a composition for the application in the said method
EP0919228A4 (en) 1996-08-02 2001-12-12 Hisamitsu Pharmaceutical Co Capsules for oral preparations and capsule preparations for oral administration
DE69732983T2 (en) 1996-09-13 2006-02-16 Shionogi & Co., Ltd. Sustained-release preparation using a thermal conversion as well as processes for their preparation
WO1998015263A3 (en) 1996-10-09 1998-06-11 Toshiharu Beppu A method for producing a microparticle
US5807580A (en) * 1996-10-30 1998-09-15 Mcneil-Ppc, Inc. Film coated tablet compositions having enhanced disintegration characteristics
DE19646392A1 (en) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Preparation for use in the oral cavity with a pressure-sensitive adhesive to the mucous membrane, pharmaceuticals or cosmetics for the metered delivery containing layer
US5776479A (en) 1996-12-20 1998-07-07 The United States Of America As Represented By The Secretary Of Agriculture Stable, germicidal film-forming teat-dip solutions
US6183808B1 (en) 1997-01-06 2001-02-06 Bpsi Holdings, Inc. Film coatings and film coating compositions based on dextrin
JP4409633B2 (en) 1997-01-06 2010-02-03 ベルウインド・フアーマースーテイカル・サービセス・インコーポレイテッド Film Cote queuing and film quotes queuing composition based on dextrin
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5922352A (en) 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
DE69826660D1 (en) 1997-06-11 2004-11-04 Procter & Gamble Film-coated tablet for improved compatibility in the upper gastrointestinal tract
WO1998058654A1 (en) 1997-06-20 1998-12-30 Ohkura Pharmaceutical Co., Ltd. Gelled composition
US6066336A (en) 1997-09-29 2000-05-23 Bristol-Myers Squibb Company Cholesterol-lowering tablets
WO1999022769A1 (en) 1997-10-31 1999-05-14 Monsanto Company Gellan gum tablet coating
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JP3051199U (en) 1998-02-06 1998-08-11 ダイヤ製薬株式会社 Nose pack
ES2294837T3 (en) 1998-03-11 2008-04-01 Warner-Lambert Company Llc Polyvinyl alcohol compositions.
CA2326183A1 (en) 1998-04-02 1999-10-14 Genencor International, Inc. Modified starch coating
US6270804B1 (en) 1998-04-03 2001-08-07 Biovail Technologies Ltd. Sachet formulations
US6214376B1 (en) 1998-08-25 2001-04-10 Banner Pharmacaps, Inc. Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
CN1297601C (en) 1998-09-30 2007-01-31 沃纳-兰伯特公司 Modified starch film compositions and uses thereoof
FR2783832A1 (en) 1998-09-30 2000-03-31 Warner Lambert Co Compositions for manufacture of pharmaceutical capsules comprise hydroxy propylated starch and hydrocolloid plus cation hardening system
US6635275B1 (en) * 1999-01-29 2003-10-21 Warner-Lambert Company Modified starch film compositions
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
EP1169022A4 (en) 1999-02-22 2003-05-07 Berwind Pharma Service Elegant film coating system
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US6228400B1 (en) 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
WO2001026633A1 (en) 1999-10-11 2001-04-19 Monsanto Company Tablets coated with locust bean gum, guar gum or carrageenan gum
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6274162B1 (en) 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
US6420473B1 (en) 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6375981B1 (en) 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6579545B2 (en) 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698220A (en) * 1988-08-30 1997-12-16 Pfizer Inc. Asymmetric membranes in delivery devices
US5560926A (en) * 1993-02-10 1996-10-01 Merck Patent Gesellschaft Mit Beschrankter Haftung Process for the production of an S-ibuprofen-containing tablet
US5411746A (en) * 1993-02-24 1995-05-02 Warner-Jenkinson Company, Inc. Dye compositions and methods for film coating tablets and the like
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5681684A (en) * 1995-09-20 1997-10-28 National Starch And Chemical Investment Holding Corporation Photosensitive resin composition
US6113945A (en) * 1996-02-26 2000-09-05 L. Perrigo Company Multi-colored medicament

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253312A1 (en) * 2001-09-28 2004-12-16 Sowden Harry S. Immediate release dosage form comprising shell having openings therein
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
US20070213411A1 (en) * 2003-11-05 2007-09-13 The Australian National University Dispersions And Methods Of Preparing Them
US20050152970A1 (en) * 2004-01-13 2005-07-14 Rinker Roger A. Rapidly disintegrating gelatinous coated tablets
US20050152971A1 (en) * 2004-01-13 2005-07-14 Rinker Roger A. Rapidly disintegrating gelatinous coated tablets
US9149438B2 (en) 2004-01-13 2015-10-06 Johnson & Johnson Consumer Inc. Rapidly disintegrating gelatinous coated tablets
US8815290B2 (en) 2004-01-13 2014-08-26 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US20110086098A1 (en) * 2004-01-13 2011-04-14 Rinker Roger A Rapidly disintegrating gelatinous coated tablets
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US10092521B2 (en) 2004-01-13 2018-10-09 Johnson & Johnson Consumer Inc. Rapidly disintegrating gelatinous coated tablets
WO2006022805A1 (en) 2004-07-23 2006-03-02 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
EP2098224A1 (en) 2004-07-23 2009-09-09 Mcneil-PPC, Inc Rapidly disintegrating gelatinous coated tablets
US8007825B2 (en) 2005-09-30 2011-08-30 Mcneil-Ppc, Inc. Oral compositions containing a salivation inducing agent
US20090191267A1 (en) * 2005-09-30 2009-07-30 Wynn David W Oral Compositions Containing a Salivation Inducing Agent
US7674396B2 (en) * 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
US20070104755A1 (en) * 2005-11-08 2007-05-10 Sterling Bernhard B Method and system for treatment of eating disorders
US20070104754A1 (en) * 2005-11-08 2007-05-10 Sterling Bernhard B Method and system for treatment of eating disorders
US7879355B2 (en) * 2005-11-08 2011-02-01 Plensat Llc Method and system for treatment of eating disorders
US20090074866A1 (en) * 2007-09-17 2009-03-19 Jen-Chi Chen Dip coated compositions containing copolymer of polyvinyl alcohol and polyethylene glycol and a gum
US20090208574A1 (en) * 2008-02-19 2009-08-20 Jen-Chi Chen Dip coated compositions containing a starch having a high amylose content
US8722089B2 (en) 2008-02-19 2014-05-13 Mcneil-Ppc, Inc. Dip coated compositions containing a starch having a high amylose content
US20110135694A1 (en) * 2009-12-07 2011-06-09 Saumitra Bagchi Partial dip coating of dosage forms for modified release
WO2011071877A2 (en) 2009-12-07 2011-06-16 Mcneil-Ppc, Inc. Partial dip coating of dosage forms for modified release
US9259394B2 (en) 2009-12-07 2016-02-16 Johnson & Johnson Consumer Inc. Partial dip coating of dosage forms for modified release
US8435545B2 (en) 2011-09-01 2013-05-07 Qualicaps, Inc. Capsule having broad color spectrum
US8420057B2 (en) 2011-09-01 2013-04-16 Qualicaps, Inc. Capsule having broad color spectrum

Also Published As

Publication number Publication date Type
EP1260219A3 (en) 2003-05-21 application
EP1260219A2 (en) 2002-11-27 application
US20070259098A1 (en) 2007-11-08 application
ES2323526T3 (en) 2009-07-20 grant
EP1260219B1 (en) 2009-04-08 grant
DE60231850D1 (en) 2009-05-20 grant
US7785650B2 (en) 2010-08-31 grant
CA2386339A1 (en) 2002-11-15 application
KR20020087370A (en) 2002-11-22 application
CA2386339C (en) 2010-12-07 grant
CN1388189A (en) 2003-01-01 application
JP2003012561A (en) 2003-01-15 application

Similar Documents

Publication Publication Date Title
US6517865B2 (en) Polymer film compositions for capsules
US6805881B1 (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
US20050042277A1 (en) Pharmaceutical compositions having a swellable coating
US6448323B1 (en) Film coatings and film coating compositions based on polyvinyl alcohol
US5006362A (en) Branding pharmaceutical dosage forms, food and confectionery products with aqueous ingestible inks
US5098715A (en) Flavored film-coated tablet
US5224989A (en) Film-forming dispersion for a protective coating of drug and food containing articles and objects
US7101573B2 (en) Simethicone solid oral dosage form
US5470581A (en) Aqueous maltodextrin and cellulosic polymer film coatings
US4828841A (en) Maltodextrin coating
US5330759A (en) Enteric coated soft capsules and method of preparation thereof
US7790215B2 (en) Sustained-release gel coated compositions
US20030211146A1 (en) Modified starch film compositions
US6420473B1 (en) Acrylic enteric coating compositions
US6902609B2 (en) Pearlescent film coating systems and substrates coated therewith
US6468561B1 (en) Aqueous film coating with improved properties
US5635208A (en) Granulation process for producing an acetaminophen and diphenhydramine hydrochloride composition and composition produced by same
US5206030A (en) Film-forming composition and use for coating pharmaceuticals, foods and the like
US20040062804A1 (en) Modified release dosage forms
US20060165778A1 (en) Enteric composition for the manufacture of soft capsule wall
US3420931A (en) Pharmaceutical dragee
US5658589A (en) Subcoated simulated capsule-like medicament
WO1995022962A1 (en) Controlled release composition
US20060204587A1 (en) Use of film coating as taste-masking coating of oral dosage forms
US20050107498A1 (en) Rapidly soluble film covering based on polyvinylalcohol-polyether graft copolymers combined with components containing hydroxyl, amide, or ester functions

Legal Events

Date Code Title Description
AS Assignment

Owner name: MCNEIL-PPC, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GULIAN, CYNTHIA;GOWAN, WALTER G., JR.;PAREKH, KISHOR B.;AND OTHERS;REEL/FRAME:013025/0201;SIGNING DATES FROM 20020417 TO 20020422